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Challenges in the Pharmacokinetics of Therapeutic Proteins
Abstract
Due to the complex structure and complicated disposition pattern of therapeutic macromolecules, their
pharmacokinetic interpretation has many challenges. Two of these challenges were investigated in this
dissertation: 1) the error of classical bioavailability assessment observed during subcutaneous (SC)
administration of therapeutic macromolecules that undergo target-mediated drug disposition (TMDD) and
2) the ontogeny of the neonatal Fc receptor (FcRn) expression along with its effect on the
pharmacokinetics of monoclonal antibodies (mAbs) during development.
TMDD often well describes the pharmacokinetics of therapeutic proteins that have high specificity and
affinity of binding to their target receptors. The target receptors can be saturated by therapeutic proteins
under therapeutic concentration due to their limited expression and availability in the body. Consequently,
clearance through this pathway will reach its maximum and nonlinear pharmacokinetics will be observed
upon further increasing dose if TMDD is a major elimination process. This, in turn, will impact the
bioavailability estimation. Bioavailability estimations based on the classic AUC approach can be
erroneous in this situation, mainly due to the incorrect assumption of dose-independent constant
clearance that cannot be applied to therapeutic proteins that undergo TMDD. To shed light on this issue, a
simulation study was performed with two model drugs: filgrastim and denosumab. Their published
structural pharmacokinetic models and model parameters were employed in the simulations of plasma
concentration-time profiles at different IV and SC doses. The bioavailability was calculated as the ratio of
dose-normalized AUC after SC administration to that after IV administration.
The overestimation was extreme when high SC and low IV doses of both protein drugs were used for the
estimations, whereas excessive underestimation was observed with the combination of low SC and high
IV doses. These biases in the bioavailability estimation resulted from the transition from low plasma
concentration (at low doses) to high plasma concentration (at high doses), which shifted the major
elimination pathway from TMDD to the unspecific linear clearance pathway. The changes in clearance
resulted in parallel changes in dosenormalized AUCs and were very dynamic in the dose range of 0.1 – 5
µg/kg for filgrastim and below 60 mg for denosumab; thus caution is necessary when bioavailability of
these two therapeutic proteins is estimated in these dose ranges using conventional method. To
minimize the error of conventional bioavailability estimation of protein drugs that undergo TMDD, the
bioavailability should be estimated at similar IV and SC doses or the assessment should be performed in
dose ranges that yield constant dose-normalized AUCs (0.01 – 0.1 µg/kg or 5 – 10000 µg/kg for
filgrastim, and 60 – 210 mg for denosumab). Moreover, an alternative estimation method could be
applied, which determines the ratio of IV and SC doses that generate equally shaped concentration-time
profile by applying a variable rate IV infusion, thereby resulting in equal AUCs as suggested by others.
FcRn has been evidenced as a salvage pathway from lysosomal clearance for mAbs and Fc conjugated
proteins; thus it can prolong the existence of these protein drugs in systemic circulation. The ontogeny of
FcRn expression and its effect on the pharmacokinetics of mAbs should be of special concern if
therapeutic mAbs are used in both pediatrics and adults. The down-regulation of FcRn during the
development may shortened the half-life of therapeutic mAbs observed in adults. To address this
problem, FcRn expression was quantified in various organs of C57BL/6J mice from postnatal days 2
through 70, the pharmacokinetics of AMG589 were studied in different age groups of C57BL/6J mice, and
the correlation between the FcRn expression levels and the pharmacokinetics of AMG589 at various
developmental stages of mice were explored using a nonlinear-mixed effects modeling-based population
pharmacokinetic approach.
FcRn showed ontogenetic changes in liver, lungs, and kidneys. Two-fold increases in FcRn expression

were observed in liver and lungs of 10-day-old mice, whereas FcRn expression in the kidneys was doubled
in 10- and 42-day-old mice. However, the ontogeny of FcRn expression could not be correlated to the
prolonged persistence of AMG589 observed in 42 day old mice. A population pharmacokinetic approach
revealed that after accounting for the effect of body weight by allometric scaling, age and FcRn
expression in skin influenced the pharmacokinetics of AMG589 in different age groups of mice.
Decreasing volume of distribution of AMG589 was observed during development. Interestingly, clearance
of AMG589 was negatively correlated with the expression of FcRn in the skin, even though FcRn
expression in skin did not show any ontogeny. These results suggest that body weight, age, and FcRn
expression in skin could affect the pharmacokinetics of fully-human mAbs. However, regardless of the
species difference in physiology, body weight should be considered during dosage regimen design,
especially for pediatric patients who show a highly dynamic change in body size at early age.
In summary, the findings in this dissertation have pointed out the weakness of the classical bioavailability
estimation for protein drugs that undergo TMDD and have determined the factors that should be
considered for dose adjustments of therapeutic mAbs in different-aged populations.
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ABSTRACT
Due to the complex structure and complicated disposition pattern of therapeutic
macromolecules, their pharmacokinetic interpretation has many challenges. Two of these
challenges were investigated in this dissertation: 1) the error of classical bioavailability
assessment observed during subcutaneous (SC) administration of therapeutic
macromolecules that undergo target-mediated drug disposition (TMDD) and 2) the
ontogeny of the neonatal Fc receptor (FcRn) expression along with its effect on the
pharmacokinetics of monoclonal antibodies (mAbs) during development.
TMDD often well describes the pharmacokinetics of therapeutic proteins that
have high specificity and affinity of binding to their target receptors. The target receptors
can be saturated by therapeutic proteins under therapeutic concentration due to their
limited expression and availability in the body. Consequently, clearance through this
pathway will reach its maximum and nonlinear pharmacokinetics will be observed upon
further increasing dose if TMDD is a major elimination process. This, in turn, will impact
the bioavailability estimation. Bioavailability estimations based on the classic AUC
approach can be erroneous in this situation, mainly due to the incorrect assumption of
dose-independent constant clearance that cannot be applied to therapeutic proteins that
undergo TMDD. To shed light on this issue, a simulation study was performed with two
model drugs: filgrastim and denosumab. Their published structural pharmacokinetic
models and model parameters were employed in the simulations of plasma concentrationtime profiles at different IV and SC doses. The bioavailability was calculated as the ratio
of dose-normalized AUC after SC administration to that after IV administration.
The overestimation was extreme when high SC and low IV doses of both protein
drugs were used for the estimations, whereas excessive underestimation was observed
with the combination of low SC and high IV doses. These biases in the bioavailability
estimation resulted from the transition from low plasma concentration (at low doses) to
high plasma concentration (at high doses), which shifted the major elimination pathway
from TMDD to the unspecific linear clearance pathway. The changes in clearance
resulted in parallel changes in dose-normalized AUCs and were very dynamic in the dose
range of 0.1 ± 5 g/kg for filgrastim and below 60 mg for denosumab; thus caution is
necessary when bioavailability of these two therapeutic proteins is estimated in these
dose ranges using conventional method. To minimize the error of conventional
bioavailability estimation of protein drugs that undergo TMDD, the bioavailability should
be estimated at similar IV and SC doses or the assessment should be performed in dose
ranges that yield constant dose-normalized AUCs (0.01 ± 0.1 g/kg or 5 ± 10000 g/kg
for filgrastim, and 60 ± 210 mg for denosumab). Moreover, an alternative estimation
method could be applied, which determines the ratio of IV and SC doses that generate
equally shaped concentration-time profile by applying a variable rate IV infusion, thereby
resulting in equal AUCs as suggested by RWKHUV
FcRn has been evidenced as a salvage pathway from lysosomal clearance for
mAbs and Fc conjugated proteins; thus it can prolong the existence of these protein drugs
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in systemic circulation. The ontogeny of FcRn expression and its effect on the
pharmacokinetics of mAbs should be of special concern if therapeutic mAbs are used in
both pediatrics and adults. The down-regulation of FcRn during the development may
shortened the half-life of therapeutic mAbs observed in adults. To address this problem,
FcRn expression was quantified in various organs of C57BL/6J mice from postnatal days
2 through 70, the pharmacokinetics of AMG589 were studied in different age groups of
C57BL/6J mice, and the correlation between the FcRn expression levels and the
pharmacokinetics of AMG589 at various developmental stages of mice were explored
using a nonlinear-mixed effects modeling-based population pharmacokinetic approach.
FcRn showed ontogenetic changes in liver, lungs, and kidneys. Two-fold
increases in FcRn expression were observed in liver and lungs of 10-day-old mice,
whereas FcRn expression in the kidneys was doubled in 10- and 42-day-old mice.
However, the ontogeny of FcRn expression could not be correlated to the prolonged
persistence of AMG589 observed in 42 day old mice. A population pharmacokinetic
approach revealed that after accounting for the effect of body weight by allometric
scaling, age and FcRn expression in skin influenced the pharmacokinetics of AMG589 in
different age groups of mice. Decreasing volume of distribution of AMG589 was
observed during development. Interestingly, clearance of AMG589 was negatively
correlated with the expression of FcRn in the skin, even though FcRn expression in skin
did not show any ontogeny. These results suggest that body weight, age, and FcRn
expression in skin could affect the pharmacokinetics of fully-human mAbs. However,
regardless of the species difference in physiology, body weight should be considered
during dosage regimen design, especially for pediatric patients who show a highly
dynamic change in body size at early age.
In summary, the findings in this dissertation have pointed out the weakness of the
classical bioavailability estimation for protein drugs that undergo TMDD and have
determined the factors that should be considered for dose adjustments of therapeutic
mAbs in different-aged populations.
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CHAPTER 1.

BACKGROUND

Advances in biotechnology have created a new era of therapeutic molecules,
transitioning from chemically-defined small molecules to biotechnologically-derived
large proteins. The application of biotechnologically-derived products as therapeutics has
gained much attention due to several advantages they have over small molecule drugs.
These advantages include a highly-specific and complex set of functions that cannot be
mimicked by simple chemical compounds, a low propensity of adverse events due to
their oftentimes highly-specific effect on a defined target with limited or no off-target
activity, and far-reaching patent protection as a consequence of the unique forms and
functions defined by their complex in vivo production process [1]. These superiorities
have resulted in the expanded use of therapeutic proteins in clinical therapy.
Similar to small molecule drugs, successful therapy with therapeutic proteins can
only be achieved with an effective dosage regimen that has been designed with the
appreciation and application of pharmacokinetic and pharmacodynamic principles. The
challenges in the pharmacokinetics and pharmacodynamics of protein drugs arise from
some of their specific properties, including the structural similarity to endogenous
proteins and nutrients, their intimate involvement in physiologic processes on the
molecular level that often include regulatory feedback mechanisms, and their large
molecular weight and macromolecule character [2, 3]. To gain insight into the
pharmacokinetic properties of protein therapeutics, all relevant processes are described in
general in this chapter as background for further discussion in subsequent chapters.
Further interest in the pharmacokinetics of therapeutic proteins should be referred to
several extensive reviews that were used as a basis for this chapter [2-8].
Pharmacokinetics of Protein Therapeutics
The in vivo disposition of protein drugs can be predicted to a large extent from
their physiological function. The short elimination half-life can be expected from small
proteins with hormone activity, which is desirable for close regulation of endogenous
levels and thus function. In contrast, long half-lives of several days are usually observed
for proteins with transport function (such as albumin) and long-term immune function
(such as immunoglobulins) to ensure the continuous maintenance of physiologicallynecessary concentrations in systemic circulation [2, 3]. Similar to small-molecule
compounds, the processes involved in the pharmacokinetics of protein drugs generally
include absorption, distribution, and elimination. However, the special processes entailed
in the disposition of protein drugs may involve target receptor-mediated drug disposition,
and interaction with Fc receptors. These two pathways play major roles in the
pharmacokinetics of monoclonal antibodies (mAbs).

1

Absorption
The susceptibility of proteins to the digestive enzymes in the gastrointestinal tract,
along with their physicochemical properties such as size and charge, hampers their
absorption process through the gastrointestinal membranes and creates challenges in
delivering protein therapeutics in oral dosage forms. Because of this limitation, the
currently available dosages for protein therapeutics is injection or infusion via
intravenous (IV), subcutaneous (SC), or intramuscular (IM) administration.
However, these administration routes have many drawbacks. Although IV
administration such as bolus injection or infusion is preferred as a means to directly
deliver peptides and proteins into the systemic circulation, it is inconvenient and might
not provide the desired concentration-time profile. Moreover, the potentially decreased
bioavailability with SC and IM injections is a disadvantage that has to be considered. The
decreased bioavailability is due to variables such as local blood flow, injection trauma,
protein degradation at the site of injection or in the lymphatic system, and limitations of
uptake into the systemic circulation related to effective capillary pore size, convection,
and diffusion.
After SC administration, proteins may enter the systemic circulation via blood
capillaries or lymphatic vessels. The primary pathways for systemic absorption include
diffusion across blood vessels distributed near the injection site and convective transport
through lymphatic vessels and into the blood. There appears to be a linear relationship
between molecular weight and the proportion of the dose entering the lymphatic system.
The absorption into the systemic circulation after SC or IM administration is slow and it
generally takes a few days to one week to reach peak plasma concentrations. The
absolute bioavailability of mAbs is generally reported between 50 and 100% [5, 6]. The
bioavailability of mAbs depends on the rates of extravascular degradation (e.g.,
proteolysis), antibody endocytosis (e.g., receptor-mediated or fluid-phase endocytosis),
and recycling through interaction with the neonatal Fc-receptor (FcRn).
Other extravascular administration routes through nasal, buccal, rectal, vaginal,
transdermal, ocular, and pulmonary drug delivery have also been shown promising
results and are under development to improve bioavailability through improved systemic
absorption.
Distribution
Similar to conventional small-molecule drugs, protein drugs have to extravasate
across the endothelial walls of vascular capillaries, pass through the interstitium, and
reach the target sites in order to exert their pharmacological activity. The extravasation of
protein drugs to the target site can involve convection or transcytosis. The rate and extent
of protein extravasation are determined largely by their size and molecular weight,
physiochemical properties (e.g. charge, lipophilicity), protein binding, and their
dependency on active transport processes. Biological factors including regional
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differences in capillary structures, the disease state of an organ or tissue, and the flow rate
of blood can also affect the extravasation and distribution of macromolecules. Due to
their high molecular weight and large size, the distribution of most proteins is limited to
the extracellular space. This leads to small apparent volumes of distribution for most
proteins. Protein drugs with higher molecular weights will distribute in smaller
distribution volumes than protein drugs with lower molecular weights, resulting in lower
interstitial concentrations with increasing molecular weights. However, active tissue
uptake and binding to extravascular proteins and other structures can substantially
increase the apparent volume of distribution of protein drugs.
In contrast to small-molecule drugs, convection rather than diffusion is the main
process that transports proteins from the vascular space into the interstitial space of
tissues. The convection process occurs as a unidirectional fluid flux from the vascular
space through paracellular pores into the interstitial tissue space. This process is the main
pathway of protein transport and is largely determined by the rate of fluid movement
from blood to tissue and by the sieving effect of paracellular pores in the vascular
endothelium. The sieving effect is mainly determined by the size and tortuosity of
membrane pores and by the size, shape, and charge of protein drugs. As pore size
decreases and the tortuosity increases, there is an increased resistance to the movement of
macromolecules. Proteins in the interstitial tissue space are subsequently removed by
convective transport via lymph drainage back into the systemic circulation. Compared to
extravasation, lymph drainage is a much more efficient process due to the much larger
size of paracellular pores in lymphatic vessels compared to the vascular endothelium. As
a consequence of the difference in the efficiency of convective uptake into tissue and
convective drainage of proteins from tissue, protein concentrations in tissue interstitial
fluid are substantially lower than protein concentration in plasma. However, higher
concentrations of proteins can be observed in tissues with leaky vasculature (e.g. bone
marrow and spleen).
In addition to the size-dependent sieving of macromolecules through the capillary
walls, the charge may also play an important role in the biodistribution of proteins. Due
to the abundance of glycosaminoglycans in the extracellular matrix that impart a negative
charge on most cell surfaces, the rate and extent of distribution into tissues is increased
by the electrostatic attraction between negatively-charged cell membranes and proteins
that are positively charged.
Another pathway for the transfer of protein molecules from the vascular to the
interstitial space is transcytosis, which is a transcellular transport pathway that couples
endocytosis and exocytosis on the opposite plasma membranes of cells. However, for
most proteins, convection is quantitatively more important than transcytosis in terms of
extravasation of protein drugs from the systemic circulation.
Protein binding is another factor that can affect the volume of distribution and
cause an inhibitory or stimulatory effect on the biological activity of protein therapeutics.
Upon binding, endogenous binding proteins can serve as the storage depot for therapeutic
proteins that result in prolonged plasma concentration-time profiles; alternately, they can
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enhance protein clearance. Moreover, cellular uptake processes may be facilitated by
interaction with specific binding proteins and thus affect the pharmacodynamics.
Besides physicochemical properties and protein binding, site-specific receptormediated uptake can also substantially affect the distribution of protein therapeutics.
Elimination and pharmacodynamics can also be influenced by this receptor-mediated
uptake process, which can be explained by target-mediated drug disposition (TMDD)
pharmacokinetics. This is normally observed for therapeutic mAbs that are designed to
bind membrane-standing target antigens with high affinity, which will affect the
distribution of the drug and result in low volumes of distribution (approximately equal to
the plasma volume). This is due to the tight binding of mAbs to cells near the sites of
antibody extravasation, which is known as the ³ELQGLQJ-VLWHEDUULHU´K\SRWKHVLV
However, antibody fragments consisting of only an antigen-binding portion (Fab
fragments) or single-chain variable fragments can cross the blood-tissue barrier more
easily and are less hindered by the binding-site barrier.
After IV administration, proteins usually follow a bi-exponential plasma
concentration-time profile well described by a two-compartmental model. The central
compartment in this two-compartmental model principally represents the vascular space
and the interstitial space of well-perfused organs such as liver and kidneys, which have
permeable capillary walls. The peripheral compartment illustrates the interstitial space of
the poorly-perfused organs with the slow equilibrium of the drug concentration [2, 3, 7].
Elimination
Protein therapeutics use the same catabolic pathways as endogenous or dietary
proteins, which feeds into an amino acid pool that can be reused for the biosynthesis of
structural or functional body proteins. The elimination processes of proteins include
proteolysis, renal elimination, hepatic elimination, or receptor-mediated endocytosis.
However, non-metabolic elimination pathways such as renal or biliary excretion are
negligible for most proteins. If biliary excretion occurs, it is usually followed by
metabolic degradation in the gastrointestinal tract. The metabolic rate for protein
degradation generally increases with decreasing molecular weight from large to small
proteins to peptides. The degradation rate also depends on other factors, such as size,
charge, lipophilicity, functional groups, and glycosylation pattern as well as secondary
and tertiary structure.
Proteolysis. Protein therapeutics can be metabolized throughout the body because
of the ubiquitous availability of proteolytic enzymes. Thus, locations of intensive peptide
and protein metabolism are not only limited to liver, kidney, and gastrointestinal tract but
can also include blood and other body tissues. Proteases and peptidases are also located
within cells; thus, intracellular uptake per se is more an elimination than a distribution
process. There are two major mechanisms by which proteins are degraded intracellularly
²the lysosomal pathway and the ubiquitin-mediated pathway. These two pathways work
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together in the degradation of intracellular proteins and exogenous proteins. While
peptidases and proteases in the gastrointestinal tract and in lysosomes are relatively
nonspecific, soluble peptidases in the interstitial space and exopeptidases on the cell
surface have a higher selectivity and determine the specific metabolism pattern of an
organ.
Renal Elimination [2, 3, 7]. The kidneys are a major site of metabolism for
smaller-sized proteins that undergo glomerular filtration. The cut-off size for glomerular
filtration is approximately 60 kDa with the effective molecule diameter (based on
molecular weight and conformation) or hydrodynamic radius as a potential limiting
factor. However, glomerular filtration is most efficient for proteins that are smaller than
30 kDa.
Peptides and small proteins (<5 kDa) are filtered very efficiently, and their
glomerular filtration clearance reaches the maximal glomerular filtration rate (GFR, ~
120 mL/min in humans). In contrast, the filtration rate of proteins greater than 30 kDa
abruptly declines. In addition to size, charge selectivity has also been observed for
glomerular filtration. Anionic macromolecules pass through the filtration membranes less
readily than neutral macromolecules, which in turn pass through less readily than cationic
macromolecules.
Renal elimination of small proteins can occur through one of three routes,
resulting in negligible amounts of intact molecules detected in urine. The first route
involves glomerular filtration of larger, complex peptides and proteins followed by
reabsorption into endocytic vesicles in the proximal tubule, and subsequent hydrolysis
into small peptide fragments and amino acids. The second major route entails glomerular
filtration followed by intraluminal metabolism by brush border membrane enzymes
located on the luminal membrane of the proximal tubule. The resulting peptide fragments
and amino acids are reabsorbed into the systemic circulation. The third route is the
peritubular extraction of proteins from postglomerular capillaries with subsequent
intracellular metabolism.
For the first two mechanisms, glomerular filtration is the rate-limiting step as
subsequent degradation processes are unsaturated under physiologic conditions. Due to
this limitation, the renal contribution to the overall elimination of proteins is dependent
on the proteolysis that occurs in other regions of the body. If proteolysis is high in other
body regions, renal contribution to total clearance will be limited, and becomes negligible
in the presence of nonspecific degradation throughout the body. If metabolic activity for
proteins is low in other tissues, or distribution to the extravascular space is limited, the
renal contribution to the overall clearance may reach 100%. In general, mAbs are not
eliminated by this pathway due to their large size, preventing renal filtration. However,
Fab fragment-based therapeutics can be excreted to some extent by the kidneys.
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Hepatic Elimination [2, 3]. A prerequisite for hepatic metabolism of proteins is
the uptake into one of three cell types in the liver: hepatocytes, Kupffer cell, and
endothelial cells.
Hydrophobic small peptides can either cross the hepatocyte membrane via simple
passive diffusion if they have sufficient hydrophobicity or be taken up by the hepatocytes
via a carrier-mediated transport. After internalization into the cytosol, these peptides are
usually metabolized by microsomal enzymes. Peptides that enter the liver via carriermediated transport are typically excreted into the bile by active export transporters.
Uptake of larger peptides and proteins is facilitated via various carrier-mediated,
energy-dependent transport processes such as receptor-mediated endocytosis. In receptormediated endocytosis, circulating peptides and proteins are recognized by specific
hepatic receptor proteins, which are usually integral membrane glycoproteins with an
exposed binding domain on the extracellular side of the cell membrane. For
glycoproteins, if a critical number of exposed sugar groups (such as mannose, galactose,
fucose, N-acetylglucosamine, N-acetylgalactosamine, or glucose) is exceeded, receptormediated endocytosis through sugar-recognizing receptors is an efficient hepatic uptake
mechanism. Important carbohydrate receptors in the liver are the asialoglycoprotein
receptor in hepatocytes and the mannose receptor in Kupffer and hepatic endothelial
cells. Moreover, low-density lipoprotein (LDL)-receptor-related protein (LRP) is a
member of the LDL receptor family, responsible for endocytosis of several important
lipoproteins, proteases, and protease-inhibitor complexes in the liver and other tissues.
Uptake of proteins by hepatic cell types is followed by transport to an intracellular
compartment for metabolism. Proteins internalized into vesicles via an endocytotic
mechanism undergo intracellular transport towards the lysosomal compartment near the
center of the cell. The endocytotic vesicles then fuse with or mature into lysosomes,
which are specialized acidic vesicles that contain a variety of hydrolases capable of
degrading all biological macromolecules. The hepatic metabolism of glycoproteins may
occur more slowly than with naked proteins because protecting oligosaccharide chains
need to be removed first. Peptide and protein metabolites in lysosomes from hepatocytes,
hepatic sinusoidal cells, and Kupffer cells may be released into the systemic circulation.
Degraded proteins in hepatocyte lysosomes can also be delivered to the bile canalicul and
excreted by exocytosis.
Another intracellular, usually minor elimination pathway for proteins is the direct
shuttle or transcytotic pathway. The endocytotic vesicle formed at the cell surface
traverses the cell to the peribiliary space, where it fuses with the bile canalicular
membrane, releasing its contents by exocytosis into bile.
Receptor-Mediated Metabolism/Target-Mediated Drug Disposition (TMDD).
Unlike conventional small molecule drugs, receptor-mediated metabolism is a substantial
elimination pathway for many therapeutic proteins. This is due to their high binding
affinity to their target receptors along with the significant amount of protein drugs that is
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normally involved in the target binding. The binding can lead to cellular uptake by
receptor-mediated endocytosis and subsequent intracellular lysosomal degradation. This
high-affinity, low-capacity binding process can occur in any organ and tissue that
expresses specific receptors for the therapeutic protein, and thus contributes to the
elimination of therapeutic proteins throughout the body. Thus, the process of receptormediated endocytosis contributes significantly not only to the pharmacodynamics but
also to the pharmacokinetics of protein drugs.
For therapeutic proteins that have their target receptors on the cell surfaces, the
elimination that occurs through receptor-mediated endocytosis can be described by
target-mediated drug disposition pharmacokinetics. For mAbs, this process occurs via the
interaction between the Fab portion of mAbs and the target epitopes on the cell surface.
Since the number of target receptors is limited, this process can be saturated with
therapeutic concentrations. As a consequence, the clearance of therapeutic proteins that
go through this process is not constant but dose-dependent and decreases with increasing
dose. Thus, receptor-mediated elimination constitutes a major source of the nonlinear
pharmacokinetic behavior of numerous protein drugs that show over-proportional
increases in systemic exposure with increasing dose.
Elimination via the Reticuloendothelial System (RES). For mAbs, the
phagocytic cells in the immune system, such as macrophages and monocytes, are
expected to play a role in the elimination as key factors in the effector functions of
endogenous IgG. After the Fc portion of the antibody binds to the FcJ-receptors
expressed on the phagocytic cells, the internalization and subsequent degradation of IgG
by lysosomes generally occurs. Unlike receptor-mediated metabolism, this route is not
expected to be saturated by therapeutic mAb doses, because therapeutic mAb
concentrations are generally a small fraction of total endogenous IgG. However, there is
evidence that suggests that FcJ-receptor-mediated elimination has limited influence or a
merely minor effect on the plasma and tissue disposition of monomeric IgG [9-12]. This
process might be a significant and perhaps dominant pathway when antibody is able to
form soluble immune complexes containing three or more IgG molecules, and might play
an important role when antibody binds to suspended cells in blood or other body fluids
such as viruses, bacteria, platelets, erythrocytes, and leukocytes [9, 13, 14].
Polymorphisms in FCGR3AZKLFKHQFRGHV)FȖ5,,,DD)FȖ-receptor expressed
by macrophages and natural killer cells, have no influence on the pharmacokinetics of
horse anti-lymphocyte globulin in renal transplant patients [10]. 2.4G2, an antibody
directed against the murine FcII receptor on macrophages, is able to clearly reduce the
rate of clearance of immune complexes but does not alter the rate of clearance of
monomeric IgG anti-HSA [9]. With a 85-fold reduction in HAE2-IgE complex binding
WR)FȖ5,,,DQG,,,UHODWLYHWRZLOG-type IgG1, high-affinity anti-IgE antibody-2 (HAE2)
reduces clearance of HAE2-IgE complex and decreases distribution to the liver [13].
Moreover, mAb blockade of the )FȖ-receptor is shown to prolong the systemic exposure
of IgG-sensitized red blood cells in vivo [14]. Recent studies also suggest WKDW)FȖreceptors play only a minor role in the elimination of murine IgG1 mAb and endogenous
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IgGs [11, 12]. However, the mechanism of this nonspecific elimination pathway for
mAbs is still not fully understood and may differ across different mAbs.
Target-Mediated Drug Disposition
The pharmacokinetics of numerous protein therapeutics are characterized by
target-mediated drug disposition (TMDD), which occurs when binding to the
pharmacodynamic target molecule affects the pharmacokinetics of a drug compound and
results in capacity-limited, saturable processes. These saturable processes are caused by
the limited availability of enzymes, receptors, or other target protein structures with
which the drug is interacting. This results in nonlinear pharmacokinetics that show a
disproportional change in plasma concentration with increasing dose. Most notably,
TMDD is the result of receptor-mediated protein metabolism, which is a frequentlyencountered elimination pathway for many therapeutic proteins that often show saturation
at therapeutic dosage regimens. However, TMDD can affect distribution as well as
elimination processes.
To describe the processes that occur in TMDD, the general TMDD model is used
[15]. Drugs administered via various routes get into the body and appear in the blood
circulation (central compartment). The free drug in the blood circulation can distribute to
the tissues (peripheral compartment) with the first-order rate constant Kpt, and free drug
in the tissue can distribute back to the blood circulation with the first-order rate constant,
Ktp. The free drug in the blood circulation can also be eliminated by linear clearance
pathways such as proteolysis, with the first-order rate constant Ke. The drug in the blood
circulation can also bind to free receptors at the target site, which are synthesized with the
zero-order Ksyn rate and degraded with the first-order rate constant Kdeg. Drug and
receptor will form the drug-receptor complexes with the second-order rate constant Kon.
The drug-receptor complexes can dissociate back to generate the free drug with the firstorder constant Koff, or they will be internalized with the first-order rate constant Kint and
subsequently degraded. This general TMDD model can be modified to incorporate
additional compartments or factors.
For many mAbs, target-mediated elimination is probably a more important
elimination pathway than proteolysis by cells in the RES [4]. It occurs when the Fabportion of mAbs binds to the target antigen and causes internalization and subsequent
LQWUDFHOOXODUGHJUDGDWLRQLQO\VRVRPHV7KLVSURFHVVLVRIWHQUHIHUUHGWRDVµDQWLJHQVLQN¶
and is saturable because of the limited amount of the target antigen. As a consequence,
nonlinear pharmacokinetics has often been reported. However, not all mAbs show
concentration-dependent elimination. Linear elimination, in which the elimination rate
does not depend on the dose or the plasma concentration, has been reported in some
mAbs, especially for those that target a soluble antigen (not bound to cells) such as
vascular endothelial growth factor or TNFD. The reason might be that the concentrations
in plasma and tissues after therapeutic dose administration do not saturate the target
antigen, or the target-mediated clearance is of less importance when compared to other
elimination pathways.
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The Neonatal Fc Receptor (FcRn)
The neonatal Fc receptor (FcRn) or Brambell receptor is involved in a
physiological process that functions as a protective mechanism against metabolism and
elimination of IgG and albumin [4-7, 16]. Through this process, IgGs show the longest
elimination half-life compared to other isotypes of immunoglobulins (IgA, IgD, IgE, and
IgM) [4, 7]. Intact IgGs have a molecular weight of ~ 150 kDa and a valence of 2 (each
molecule of IgG contains two identical antigen-binding domains). Based on the heavy
chain structure, the IgG family can be divided into four subclasses, including IgG1, IgG2,
IgG3, and IgG4 [5, 6]. The structural difference in IgG heavy chains among the
subclasses leads to the differences in the binding to Fc receptors, and results in subclassspecific differences in processes mediated by Fc receptors (e.g., activation of
complement, or antibody-dependent cell-mediated cytotoxicity) [5]. Among the IgG
family members, IgG3 has a much shorter elimination half-life (7 days) than those of the
other IgG isotypes (20-21 days) [4, 7].
The salvage pathway by FcRn is a pH-dependent process since binding of IgG
and albumin to the FcRn occurs in acidic (pH 6.0 ± 6.5) but not in neutral (pH 7.0 ± 7.5)
environments. After nonspecific pino- or endocytosis, in which the molecule is engulfed
by the cell membrane and taken up into the cell, the Fc portion of IgG binds to the FcRn
in the slightly acidic environment of the endosomes. The IgG-FcRn complex is then
transported back to the cell surface and released into the systemic circulation at neutral
pH, whereas unbound IgG and other proteins are degraded to amino acids by intracellular
lysosomes (Figure 1-1).
FcRn can transport IgG across cell monolayers in both the apical- to basolateral
and basolateral- to apical directions. The FcRn protective mechanism has an influence on
the pharmacokinetics of endogenous IgG and albumin. The long elimination half-life (21
days) of endogenous IgG and albumin compared to other plasma proteins can be
explained by this mechanism. Saturation of FcRn can occur at high concentrations of IgG
that demolish the salvation pathway. However, this is generally not expected at the
therapeutic dose of mAbs as the usual therapeutic dose of a few hundred milligrams is
small compared to the endogenous IgG amount of 12 g/L (~50-100 g in an adult). To
saturate this protective mechanism, very high doses of therapeutic mAbs would be
needed.
The saturation of FcRn occurs in the treatment of autoimmune diseases. Highdose intravenous immunoglobulin (IVIG) therapy with pooled human IgG at a dose of 2
g/kg can sufficiently increase IgG plasma concentrations, leading to an approximately
threefold increase in IgG clearance [5, 17]. This increase in IgG clearance results in a
decrease in the plasma concentrations of endogenous, pathogenic autoantibodies.
However, IVIG therapy is very expensive due to the requirement of high doses for the
therapy. To achieve a similar effect to that of IVIG therapy, anti-FcRn antibodies can be
administered at a ~100-fold lower dose than IVIG therapy [5, 18]. These anti-FcRn
antibodies are specifically directed against FcRn or have a modified Fc portion that can
form more stable complexes with FcRn. As a result, an increase in the elimination rate of
9

Figure 1-1. Schematic illustration of the FcRn mediated recycling pathway
(A) IgG and albumin circulating in the bloodstream are continuously taken up by fluid
phase pinocytosis and enter early endosomes where FcRn predominantly resides. (B) The
acidified milieu herein facilitates binding of IgG and albumin to FcRn. (C) The ternary
complex is then recycled to the cell surface where exposure to physiological pH of the
bloodstream triggers release of IgG and albumin into the circulation. (D) When the
concentrations of IgG and albumin are high, FcRn is saturated and unbound ligands
undergo lysosomal degradation. (E) FcRn may also transcytose IgG and albumin to the
basolateral side of the cell for release into extravascular space.
Source: Reprinted with permission from The Japanese Society for the Study of
Xenobiotics (JSSX). Andersen, J.T. and I. Sandlie, The versatile MHC class I-related
FcRn protects IgG and albumin from degradation: implications for development of new
diagnostics and therapeutics. Drug Metab Pharmacokinet, 2009. 24(4): p. 318-32.
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mAbs and endogenous IgG can be achieved after the administration of anti-FcRn
antibodies [4].
The binding affinity between IgG and FcRn is species specific. High binding
affinity is observed between human FcRn and human IgG as well as guinea pig and
rabbit IgG [19]. However, human FcRn has a very low affinity to mouse, rat, bovine, and
sheep IgG. As a result, the very rapid elimination of murine mAbs in human is observed.
In contrast, mouse FcRn binds to IgG from all aforementioned species. Moreover, mouse
FcRn has higher binding affinity to human IgG1 than that observed between human FcRn
and human IgG1 [19, 20]. The difference in promiscuity for IgG-FcRn interaction
between mouse and human has raised the concerns regarding the validity of using mice as
a model to predict the pharmacokinetics of therapeutic mAbs in humans. The suitability
of mouse models for the pharmacokinetic evaluation of therapeutic mAbs has been
further called into question by another study when engineered human IgG1 was tested in
murine and human systems and exhibited different pharmacokinetics and FcRn recycling
behaviors [21]. As a consequence, a humanized FcRn transgenic mouse has been
developed and has proved to be an effective surrogate for studying the pharmacokinetics
of therapeutic mAbs and Fc-fusion proteins [22-24].
Effect of Immunogenicity on the Pharmacokinetics of Therapeutic Proteins
The origin of therapeutic proteins is important since xenogenic proteins can
trigger immune responses (immunogenicity) that cause anti-drug antibodies (ADA) to be
produced. Immunogenicity can occur when animal-derived proteins are applied in human
clinical studies as well as when human proteins are administered to animals during
preclinical studies [3]. ADAs that recognize epitopes on therapeutic proteins that are not
essential for their bioactivity are referred to as non-neutralizing antibodies (binding
antibodies) and usually result in fewer clinical consequences [8]. In contrast, ADAs that
neutralize the biological activity of therapeutic proteins by binding to their active sites
(neutralizing antibodies) frequently cause loss of efficacy. Immunogenicity can influence
the pharmacokinetics of peptide and protein drugs by altering distribution and clearance.
The direction of the immunogenic effect on pharmacokinetics is difficult to predict. The
elimination rate can be either increased or decreased, depending on the number of
antigenic sites on the exogenous proteins against which the endogenous antibodies are
directed and the size of the resulting immune complexes [4-6]. In case, only one or two
endogenous anti-drug IgGs bind to exogenous peptides or proteins, the half-life of those
exogenous peptides or proteins can approach that of endogenous IgGs that act as a depot
for therapeutic peptides or proteins. A prolonged duration of pharmacological action can
occur in this case if the antibody is not neutralized. On the other hand, simultaneous
binding of three or more anti-drug IgGs to the exogenous peptides and proteins can lead
to the very rapid elimination of the immune complex through phagocytosis by the RES.
This pharmacokinetic change resulting from the formation of antibodies against
administered proteins can affect therapeutic efficacy.
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In addition to the similarity between exogenous and endogenous proteins, the
degree of aggregation of therapeutic protein products, along with the duration of therapy,
dose, and route of administration, also have an influence on the occurrence and degree of
immunogenicity [3, 5, 6]. Immunogenicity can increase because of the quantity of
aggregates in the dosing formulation. The degree of immunogenicity can also increase
with the duration of therapy. This might be due to the increasing exposure to exogenous
proteins during prolonged therapy, which can lead to an increasing probability of antidrug antibody development against multiple antigenic sites. This in turn may result in the
rapid elimination of the therapeutic protein. The relationship between dose and
immunogenicity is difficult to predict. The clearance of drug-antibody complexes may be
delayed at low doses and increase at high doses due to the formation of aggregates that
trigger clearance through the RES. However, the inverse relationship between
immunogenicity and dose can also be observed. This inverse relationship might be due to
the presence of high amounts of protein drugs in the samples, causing assay interference
by masking the detection of anti-drug antibodies or due to the consumption of low-level
ADA by high protein drug concentrations. The route of administration may also influence
on the immunogenicity. Administration by the SC and IM route can lead to greater
immunogenicity than that observed following IV administration. The increasing
incidence of immunogenicity after extravascular administration is probably caused by a
higher numbers of protein aggregates and precipitates formed at the injection sites, which
activate immune cells and stimulate clearance through the RES.
Effect of Developmental Physiology on the Pharmacokinetics of Therapeutic
Proteins
Special considerations should be taken when using therapeutic proteins in
pediatric patients. This is due to the substantial differences between children and adults in
terms of disease etiology, the time course of the disease, disease complications or
prognosis, use of concomitant medications, immune and vaccination status, and
eventually clinical responses (including therapeutic effects and adverse drug reactions)
[8]. In addition, developmental changes in physiology that result in dynamic ageassociated changes in body composition and organ function, along with receptor
ontogeny, can affect the pharmacokinetics of protein drugs in populations of different
ages [25]. Consequently, age-associated changes in the absorption, distribution,
elimination, and immunogenicity of therapeutic proteins may be observed in pediatric
patients.
Absorption
Since therapeutic peptides and proteins are mostly administered through the IV or
SC route, developmental skin alterations may be a factor that should be considered when
protein drugs are administered to children. Compared to adults, the presence of a thinner
stratum corneum in the preterm neonate and the greater extent of cutaneous perfusion and
hydration of the epidermis throughout childhood might contribute to enhanced
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percutaneous absorption of drugs during infancy [25]. The higher ratio of total body
surface area to body mass in infants and young children compared to adults is another
factor that might affect the absorption of drugs. However, it is still inconclusive whether
differences between adults and children in the thickness of SC tissue and local lymphatic
flow at the injection site affect the absolute bioavailability of a therapeutic protein after
SC administration [8, 26].
Distribution
Developmental changes in body composition may not have a significant impact
on the biodistribution of therapeutic proteins [8]. However, a considerable alteration in
the distribution of protein drugs may be caused by changes in the composition and
amount of circulating plasma proteins and tissue targets [8, 25]. Steady-state levels of the
target antigen may differ between adult and pediatric populations due to differences in
either the production or degradation rate of the targeted antigens, which can result in
differences in the biodistribution of the therapeutic protein upon dosing [8]. Nevertheless,
the target antigens are usually overwhelmed by therapeutic proteins about a hundred- or
thousand-fold at therapeutic concentrations. Thus, the biodistribution of therapeutic
proteins at steady state might not be significantly altered by developmental changes in
antigen production or degradation rates. Instead, such differences would more likely lead
to inequalities in the elimination of therapeutic proteins if TMDD is the main pathway of
clearance.
Elimination
For many protein drugs, proteolysis occurring throughout the body is considered
to be the main pathway of clearance. Thus developmental changes in hepatic drug
metabolizing enzyme systems such as CYP have a negligible impact on the metabolism
and clearance of therapeutic proteins. Maturation in renal function may have some
influence on the excretion and elimination of small peptides that can pass through
glomerular filtration. However, the impact of developmental changes in renal function
may be negligible depending on the contribution of renal elimination to the overall
clearance that occurs in the other parts of the body.
For antibody-based therapeutic proteins, non-specific Fc receptor-mediated
GLVSRVLWLRQ WKURXJK)FȖ-receptors in RES and FcRn receptors) and target receptormediated metabolism are considered to be major elimination pathways. The elimination
through RES afWHUELQGLQJWR)FȖ-receptors has been shown to have a limited effect on
the clearance of monomeric mAbs. However, this pathway can accelerate the elimination
of antigen-DQWLERG\FRPSOH[HV7KXVWKHGLIIHUHQFHLQ)FȖ-receptor distribution between
adults and children, if it exists, might become problematic when immunogenicity occurs.
,QFRQWUDVWWR)FȖ-receptors, FcRn has been shown to play a significant role in extending
the presence of mAbs in the systemic circulation after binding to this receptor. Due to its
considerable role as a salvage pathway from clearance, potential differences in FcRn
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expression during pediatric development might result in unequal pharmacokinetic
profiles of therapeutic mAbs across different age groups. Unlike non-specific Fc
receptor-mediated disposition, target receptor-mediated clearance is a specific process
that occurs when a therapeutic protein binds to its specific receptor at the target site. The
efficiency of this mechanism depends on the target receptor expression levels and the
turnover rates of the target receptors. As a consequence, differences in the target receptor
levels and turnover rates between adults and children might be a major concern if
therapeutic proteins are mainly eliminated through this specific pathway [8, 26].
Immunogenicity
The incidence of immunogenicity from therapeutic proteins may differ between
children and adults due to variation in patient-related factors that may predispose an
individual to an immune response [8, 26]. These patient-related factors include
underlying disease, genetics, immune status, concomitant use of immunomodulators, and
previous experience using protein therapeutics. Currently, the similarities and
dissimilarities in immunogenicity between pediatrics and adults are still inconclusive.
This is due to the limited availability of immunogenicity data in pediatric populations
along with substantial shortcomings of the current technologies for ADA evaluation and
quantification. To gain insight into this matter, the improvement of assay technologies
and standardized evaluation of immunogenicity across clinical trials will be needed.
Dose Optimization of Therapeutic Proteins in Pediatric Development
Currently, the application of therapeutic proteins in pediatrics is often based on
the extrapolation of clinical findings in adults [8, 26]. The extrapolation approach may be
useful in the case that no pediatric data are available. However, this approach may
significantly compromise the efficacy and safety of pediatric patients if the differences
between children and adults are not explicitly determined. The potential considerable
differences between children and adults in terms of disease etiology, time course of
disease, disease complications or prognosis, use of concomitant medications, immune
and vaccination status, and eventually, clinical responses (including therapeutic effects
and unwanted adverse events caused by a given therapy) should all be considered in the
dosage regimen optimization. Moreover, the fundamental comprehension of the
similarities and dissimilarities in the pharmacokinetics and pharmacodynamics between
children and adults can assist in determining the rational use of therapeutic proteins in
pediatric populations.
A number of potential covariates, including target antigen levels, serum albumin
levels, disease activity, concomitant medications, and development of ADA may affect
the pharmacokinetics of protein drugs. However, the effect of body size more often
warrants dose adjustment in pediatric patients compared relative to other covariates. This
is due to the differential growth rates during development that create much larger
variability in body size for children than for adults. Because of this, the effect of body
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size is a major determinant of the pharmacokinetics of therapeutic macromolecules in
pediatrics. As a consequence, several dosing approaches that account for size alterations
during pediatric development have been successfully used in children.
To account for the size difference, weight-based (mg/kg) dosing, body surface
area (BSA)-based (mg/m2) dosing, tiered fixed dosing (i.e., a fixed dose for patients in a
specified narrow weight range), and hybrid dosing (fixed dosing for older children and
body size-based dosing for younger children) have been successfully applied. However,
both weight- and BSA-based dosing may not satisfactorily correct the body size effect, as
clearance of antibody-based therapeutic proteins is often not proportional to either weight
or BSA. To attain more physiologically-based and more accurate dose adjustment,
allometric scaling approaches have been used for dosage extrapolation from adults to
pediatric patients.
After accounting for the effect of body size, age itself has rarely been identified as
a covariate that influences the pharmacokinetics of therapeutic proteins. The available
data show that the proper correction for body size-related pharmacokinetic differences is
essential for appropriate dose selection of antibody-based therapeutic proteins for
pediatric patients. However, the body size-based dosing approach might be inefficient for
designing the dosage regimen of therapeutic proteins that are mainly eliminated through
target receptor-mediated metabolism. For these therapeutic macromolecules, differences
in the target antigen expression levels and turnover rates of the target antigens during
development may become another major determinant of pharmacokinetics. The target
receptor levels and turnover rates of the target antigen may not always increase with body
size. As a consequence, physiologically-based dose adjustment may become a better
approach to achieve a successful therapy in pediatric populations. Only very limited
clinical data are available for the use of mAbs in very young pediatric patients, including
term and preterm neonates, and further age-related adjustments beyond body size may be
warranted in this patient group.
Summary
Because susceptibility to digestive enzymes in the gastrointestinal tract, along
with limitations due to their physiochemical structure, most therapeutic proteins are
administered via the IV or SC route. The absorption of protein drugs after SC
administration occurs via convection through lymphatic vessels and diffusion across
blood capillaries. The distribution of therapeutic proteins is limited by their size and
physiochemical properties such as charge, which result in their confinement
predominantly in the vascular space. Convection and transcytosis are the two main
pathways that facilitate the distribution of protein drugs. Generally, therapeutic proteins
exhibit bi-exponential plasma concentration-time profiles upon IV administration.
Hepatic and renal excretion are negligible for therapeutic proteins. Instead, protein drugs
are usually degraded by proteolysis, which can occur throughout the body. Moreover,
target receptor-mediated catabolism is the main clearance pathway for most therapeutic
proteins that have high binding specificity to their targets. The pharmacokinetics of
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protein drugs that follow such an elimination pathway can be well described by TMDD.
For monomeric mAbs, elimination via the RES may be negligible; however, RES
becomes the main pathway of clearance of antigen-antibody complexes during when
immunogenicity occurs. The prolonged existence of mAbs in the systemic circulation can
be explained by the salvage pathway via the FcRn-mediated recycling mechanism.
Administration of therapeutic proteins can cause immunogenicity, which may lead to
prolonged exposure or abruptly-increased clearance. The occurrence of immunogenicity
can result in toxicity or lack of efficacy upon administration of protein drugs. Several
factors are responsible for the prevalence of immunogenicity, but the occurrence remains
difficult to predict in the individual patient.
Due to the physiological difference between adults and pediatric patients, the
pharmacokinetics of protein drugs may be altered during child development.
Immunogenicity reactions may also be different between adults and children. However,
current data on these differences are limited and further studies are needed in order to
elucidate differences between adults and pediatric patients in the pharmacokinetics and
immunogenicity of therapeutic proteins. Although body size-based dosing is currently
widely used for therapeutic proteins in pediatric patients, physiologically-based dosage
regimen design may be necessary for some therapeutic proteins that are influenced by
additional physiological factors such as target density and turnover.
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CHAPTER 2.

INTRODUCTION

As discussed in Chapter 1, there are many factors that contribute to the
regulation of drug disposition for protein therapeutics. As a result, the interpretation of
the pharmacokinetics for protein therapeutics presents a complex challenge. Two
challenges in the pharmacokinetic assessment of therapeutic proteins were explored in
this study.
The assessment and prediction of bioavailability after SC administration for
protein therapeutics becomes an important challenge, especially if these drugs exhibit
target-mediated drug disposition (TMDD) ± a clearance process that is dependent upon
the expression patterns and turnover rates of its target receptor. As a consequence, the
clearance of protein drugs may vary with respect to dose. With increasing dose, the
clearance through TMDD can become saturated and plateaus. However, current
bioavailability estimations use the approach of comparing dose normalized AUC from
non-intravenous routes to that of IV administration with the assumption of a doseindependent clearance. Due to failure in this assumption, an error in bioavailability
estimation may be observed for protein drugs that undergo TMDD. I hypothesized that
there is a dose-dependent error in the bioavailability assessment for therapeutic proteins
that undergo TMDD if the classical approach of dose-normalized AUC is used. The error
becomes apparent when different doses of IV and SC administration are used for
bioavailability estimations since the clearances at different IV and SC doses are not
equal. To test this hypothesis and to evaluate the errors of bioavailability estimation, I
selected two model drugs filgrastim and denosumab that undergo TMDD. Based on their
published pharmacokinetic models, the plasma concentration-time profiles of filgrastim
and denosumab were simulated in Phoenix® WinNonlin 6.3 and their bioavailabilities
were subsequently estimated. With the current bioavailability estimation approach, the
bioavailabilities of filgrastim and denosumab were determined at theoretical doses
ranging from 0.01 ± 10000 g/kg for filgrastim and 0.66 ± 210 mg for denosumab. The
errors of bioavailability assessments at different doses were subsequently determined. All
findings are described in Chapter 3.
The second challenge investigated in this study was the pharmacokinetics of
human monoclonal antibodies (mAbs) with respect to age and development. Published
studies have shown that neonatal Fc receptor (FcRn) expression is detectable up to 3
weeks postpartum in mouse intestines. Additionally, it was also postulated that a
functional role of FcRn is to salvage mAbs and Fc-fusion proteins from the degradation
or elimination pathways. Therefore, an ontogenic pattern of expression of FcRn may exist
in different organs and could potentially alter the pharmacokinetic profile of protein
therapeutics during pediatric development. These findings suggest that there is a critical
need for better predictions and assessments of PK profiles for protein therapeutics in
pediatric patients. Therefore, I conducted ex vivo analyzes of the ontogeny of FcRn
expression and described the in vivo pharmacokinetics of a model human mAb,
AMG589, in C57BL/6J mice during the post-natal developmental stages (Day 2 ± Day
70). Based on the current published evidence, my central hypothesis is that a reduced
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expression of FcRn during early postnatal development will result in a shortened half-life
of monoclonal antibody AMG589 in adult mice compared to newborn mice.
To test the main hypothesis regarding the effect of the ontogeny of FcRn
expression on the pharmacokinetics of mAbs, three experimental aims were framed. In
the first aim I examined the levels of FcRn expression in organs of C57BL/6J mice from
postnatal day 2 through day 70 (these results are described and discussed in Chapter 4).
In my second aim, I analyzed and characterized the pharmacokinetics of AMG589 in
different age groups of C57BL/6J mice (Chapter 5). Finally, in the third aim I attempted
to correlate the FcRn expression levels with the pharmacokinetics of AMG589 in the
differently aged mice using a population pharmacokinetic approach. I hypothesized that a
decrease in half-life of AMG589 in adult mice is strongly correlated to the reduced levels
of FcRn during development. To delineate the effect of FcRn expression on the
pharmacokinetics of AMG589 in different age groups of C57BL/6J mice, body size
effect was first evaluated by an allometric scaling approach, after which the effect of the
ontogeny of FcRn expression was subsequently evaluated. The results of these analyses
and their discussion are presented in Chapter 5.
The integration of my findings with the TMDD and pharmacokinetic challenges
of monoclonal antibodies in the early stages of development are summarized and
discussed in Chapter 6. The findings may help to elucidate the challenges faced in
developing and optimizing dosing regimens of mAbs for pediatric patients. The presented
studies strive to make better predictions of the pharmacokinetic profile for protein
therapeutics in order to achieve a more desirable therapeutic effects while limiting
toxicity ± this is especially important when considering the highly vulnerable pediatric
population.
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CHAPTER 3. CHALLENGES IN THE APPARENT BIOAVAILABILITY
ESTIMATION FOR THERAPEUTIC PROTEINS THAT UNDERGO TARGETMEDIATED DRUG DISPOSITION
Introduction
Target-mediated drug disposition (TMDD), the process that was first described by
Levy in 1994 [27], is the most common pathway that can well describe the
pharmacokinetics of therapeutic proteins that exert specific binding with high affinity to
pharmacological targets or receptors. Upon binding to the cell surface targets or
receptors, the internalization of the ligand-receptor complex is usually followed by
lysosomal degradation. This process causes the irreversible elimination of biotech drugs
from the body and is often the main pathway of clearance when the number of
pharmacological targets or receptors is in the same magnitude or larger than the number
of drug molecules [28]. Through this pathway, the saturable target-binding is responsible
for observable nonlinear pharmacokinetic behavior [6, 15, 27-32].
The evaluation of pharmacokinetic profiles and dose selections for these
therapeutic proteins are complicated due to this nonlinear pharmacokinetic behavior as it
results in a dose-dependent effect on the overall distribution and/or elimination
parameters [15, 29-32]. As a consequence, the rule of superposition cannot be applied
[30]. One area in which this has resulted in challenges in drug development is the
assessment of systemic bioavailability after extravascular, particularly subcutaneous
administration. For classic bioavailability assessments, dose-normalized areas-under-theplasma concentration-time curves are compared under the assumption that clearance is
constant and independent of time and route of administration. This assumption of
invariant clearance is not valid for therapeutic proteins that undergo TMDD as their
clearance mediated by the TMDD pathway is highly dependent on the degree of
saturation of this pathway and thus the concentration of the therapeutic protein. An overproportional increase in systemic exposure with increasing dose is usually observed when
elimination through receptor-mediated endocytosis starts to become saturated [28]. As a
result, an apparently dose-dependent bioavailability is frequently observed in many
therapeutic proteins including interferon-E1a (27 ± 71%) [31], filgrastim (62 ± 72%) [33]
and denosumab (36 ± 78%) [34, 35]. However, much of this apparent dose-dependency is
likely only the consequence of using bioavailability assessment methodology with the
invalid assumption of a constant clearance. The potential bias of using the standard
methodology of bioavailability estimation for therapeutic proteins that exhibit TMDD has
so far not been evaluated.
Currently, other than the full TMDD model that was first proposed by Mager et
al. [15], there are several simplified mechanistic models have been proposed to describe
the pharmacokinetic profiles of therapeutic proteins that undergo TMDD including quasiequilibrium approximation, quasi-steady-state approximation, and Michaelis-Menten
models [36-39]. The difference among these simplified models is the assumption
associated with models which can specifically well describe the pharmacokinetics of
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individual therapeutic proteins in different scenarios. With the quasi-equilibrium model,
very rapid binding between drugs and target receptors that leads to an instantaneous
equilibrium of the system is assumed. In this case, the binding process is considered very
rapid when compare to other processes. Thus, binding (Kon) and dissociation (Koff) rate
constants in the full TMDD model are difficult to obtain and are replaced by the
equilibrium dissociation constant (KD) in the quasi-equilibrium model to describe the
concentration-time profiles of drugs. However, if the rate of the internalization or
elimination of the complexes is high and cannot be negligible, quasi-steady-state
approximation model may be preferable since this model incorporates internalization rate
(Kint) in a new parameter, Kss, for describing the time course of drug concentration. For
the Michaelis-Menten model, all parameters involving the binding and internalization
processes are replaced by Km and Vmax parameters that describe capacity limitation. With
different mechanistic models, the different parameter values are obtained and these can
have the impact on the time course of drug concentration and bioavailability estimation
[40, 41].
To quantify the error that can possibly occur from the currently used
bioavailability estimation for therapeutic proteins, two model drugs, filgrastim, and
denosumab, were selected that undergo TMDD and for which a mechanistic TMDD
model had been used to quantify bioavailability. With the full TMDD model for
filgrastim and quasi-steady-state approximation of TMDD model for denosumab, the
plasma concentration-time profiles of filgrastim and denosumab were simulated at
different doses. The bioavailability was calculated using the standard AUC approach and
the effect of dose on the bias in bioavailability assessment was determined.
Method
Structural Pharmacokinetic Model
The structural models for filgrastim and denosumab were obtained from the
literature [34, 42]. A full target-mediated drug disposition (TMDD) model well described
the pharmacokinetics of filgrastim in healthy adults whereas the pharmacokinetics of
denosumab in healthy subjects and postmenopausal women with osteopenia or
osteoporosis was reasonably well described with the quasi-steady-state approximation of
the TMDD model.
TMDD Model for Filgrastim
The TMDD model for filgrastim, a recombinant methionyl human granulocyte
colony stimulating factor (r-metHuG-CSF), was developed by Wiczling and colleagues
for a population pharmacokinetic study in healthy adults [42]. This protein is used to treat
inherited and acquired neutropenia that can occur during the chemotherapy as well as to
mobilize the hematopoietic stem cells and progenitors for transplantation. The developed
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TMDD model well described the pharmacokinetics of intravenously (IV) and
subcutaneously (SC) administered filgrastim in healthy adults.
After IV and SC administration, filgrastim enters the body and is distributed
throughout the central compartment with the assumption that free G-CSF in the serum
(As) is in instantaneous equilibrium with the bone marrow and can bind to the G-CSF
receptors on neutrophilic granulocytes in blood and bone marrow. The absorption of
filgrastim after SC administration appears to follow parallel zero- and first-order
processes that concurrently occur for 6.6 hours (D2). Thereafter, there is only the firstorder absorption process present. The bioavailability associated with the first- and zeroorder absorption processes are F1 and F2, respectively. The overall bioavailability is the
summation of the bioavailability from zero- and first- order processes. In addition to GCSF from filgrastim, G-CSF is naturally synthesized at the zero-order rate which is
described by KG-CSF. Free G-CSF in the serum is eliminated with the first-order rate
constant Ke or bound to G-CSF receptors (AR) that are synthesized at the zero-order rate
Ksyn and degraded by the first-order process Kdeg. The binding process is a second-order
process with the rate constant Kon. Upon binding, the G-CSF-receptor complex is
internalized by a first-order process described by Kint or dissociates with the first-order
rate constant Koff generating free G-CSF.
Mathematically, the pharmacokinetics of filgrastim is described by the following
differential equations (Equations 3-1 to 3-3):
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(Eq. 3-1)

(Eq. 3-2)

(Eq. 3-3)

where As is the quantity of G-CSF in the serum, AR is the quantity of free receptor, and
ARC is the quantity of filgrastim-receptor complex. Kon, the association constant, is

in which KD is an equilibrium dissociation constant. The input
determined by
ವ

process can be specified by Equation 3-4.
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(Eq. 3-4)
where tinf is the infusion duration (0.5 hours), Ka is the first-order absorption rate
constant, F1 is the bioavailability of the first-order absorption process, F2 is the
bioavailability of the zero-order absorption process, D2 is the duration of zero-order
absorption, IV is the intravenous administration, and SC is the subcutaneous
administration. The absolute bioavailability equals (Equation 3-5):
 ܨൌ ܨଵ  ܨଶ

(Eq. 3-5)

The system is assumed to be in a steady-state condition prior to the administration
of the drug. Thus the relationships at baseline can be implied as (Equations 3-6 to 3-8):
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(Eq. 3-6)
(Eq. 3-7)

(Eq. 3-8)

where Cs,0 is the endogenous serum concentration of G-CSF, AR0 is the endogenous
amount of G-CSF receptors in blood and bone marrow, and ARC0 is the pre-treatment
amount of G-CSF bound receptor complexes. The concentration of G-CSF in the serum,
Cs, is determined by Equation 3-9.
ܥ௦ ൌ 

ܣ௦
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(Eq. 3-9)

Quasi-Steady-State Approximation of the TMDD Model for Denosumab
An open, two-compartment pharmacokinetic model with a quasi-steady-state
approximation of the TMDD model was developed by Sutjandra and colleagues to
describe the pharmacokinetics of denosumab in healthy subjects and postmenopausal
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women with osteopenia or osteoporosis [34]. Denosumab (AMG 162; Prolia£) is a fully
human monoclonal antibody of the IgG2 subclass that has high affinity (KD = 3 × 10-12
mol/L) and specificity for the receptor activator of nuclear factor N-B ligand (RANKL).
Upon binding of denosumab to RANKL, it prevents the binding between RANKL and its
receptor, RANK, which is expressed on pre-osteoclasts and mature osteoclasts.
Consequently, terminal differentiation, activation and survival of osteoclasts are
hampered. This results in a reduction in bone resorption and an increase in bone mineral
density (BMD).
After the SC administration of denosumab, the drug is absorbed with the firstorder process Ka. Absolute bioavailability (F) is estimated by simultaneously analyzing
the serum free denosumab concentration obtained after SC and IV administration. After
IV bolus dosing or SC absorption, free denosumab is distributed into the central
compartment that has the volume of distribution represented by V1. The non-specific
distribution from the central compartment into the peripheral compartment is
characterized by intercompartmental clearance (Q) and the peripheral volume of
distribution (V2). The free denosumab in the central compartment is eliminated by a
linear pathway quantified by CLlin, or by binding to RANKL (R) following a secondorder process (Kon) to form the denosumab-RANKL (RC) complex. The denosumabRANKL complex is dissociating according to a first-order process (Koff) and generates
free denosumab and RANKL, or is internalized through a first-order process, represented
by the rate constant Kint. RANKL is assumed to be produced following a zero-order
process, characterized by Ksyn, and degraded by a first-order process (Kdeg).
However, the denosumab-RANKL association and dissociation processes are
substantially faster than the change in denosumab disposition and elimination of the
RANKL and denosumab-RANKL complex. Therefore, the quasi-steady-state
approximation of the TMDD model is considered more suitable to describe the
pharmacokinetics of denosumab with the assumption that the drug-receptor complex is at
steady-state. Consequently, the binding rate is balanced by the sum of the dissociation

and internalization rates. Moreover, the steady-state constant (Kss), defined as ܭ   ,
is estimated since the denosumab ±RANKL binding affinity (KD), defined as
cannot be estimated independently.






,

The differential equations that are used to describe the amount of denosumab and
RANKL in the body are as follows (Equations 3-10 to 3-12):
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(Eq. 3-10)

(Eq. 3-11)
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(Eq. 3-12)

where AD, Ap, and AC represent an amount of denosumab in the depot, peripheral, and
central compartment, respectively. Rtot is the total amount of RANKL receptors which
include free and bound receptors. The total amount of denosumab (Atot) in the serum is
introduced as the sum of serum free and bound denosumab and can be estimated by the

differential Equation 3-11. The serum free denosumab concentration (Cfree = ) and the
భ

denosumab-RANKL complex are calculated as followed (Equations 3-13 to 3-14):
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(Eq. 3-13)
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(Eq. 3-14)

The total clearance in Equation 3-11 can be estimated by Equation 3-15.
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(Eq. 3-15)

The initial conditions of these differential equations (Equations 3-10 to 3-12) are
set as (Equation 3-16):
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(Eq. 3-16)

Data Simulation
By using the reported population pharmacokinetic parameters of filgrastim and
denosumab that were estimated in the original studies (Table 3-1), the plasma
concentration-time profiles for filgrastim and denosumab after IV and SC administration
were reproduced in Phoenix® WinNonlin 6.3 from the sets of equations that were
described in the structural pharmacokinetic model section. For denosumab, the
population pharmacokinetic parameters estimated from the data set that includes BLQ
data were used. The input bioavailability of SC administered filgrastim and denosumab
were set to the values of the estimated bioavailability from the original study (0.691 and
0.638 for filgrastim and denosumab, respectively [34, 42]). Simulation was also
performed with an absolute bioavailability of 1 for easier assessment of the deviation
between nominal bioavailability and the bioavailability determined by comparing AUCs.
To study dose effect on the bias of bioavailability estimation, simulations were performed
to generate the plasma concentration-time profiles of filgrastim and denosumab at various
IV and SC doses, 0.01 ± 10000 g/kg for filgrastim; and 0.66 ± 210 mg for denosumab.
These dose ranges were selected based on the evidence of usual therapeutic doses and
doses that were studied for clinical evidence or pharmacokinetic profiles of filgrastim and
denosumab. For filgrastim, the pharmacokinetic study was performed in the dose range of
2.5 ± 10 g/kg for SC administration and at 5 g/kg for IV administration [42]. The usual
therapeutic dose range for filgrastim is 1.2 - 10 g/kg [43]. For denosumab, the
population pharmacokinetic meta-analysis was implemented on the pooled data from 11
clinical studies which covered the dose range of 6 ± 210 mg of denosumab [34]. The
recommended therapeutic dose of denosumab is 120 mg via SC administration every 4
weeks [44]. However, the dose ranges that were used for simulation in this study were
expanded to the extremes, especially for filgrastim, in order to capture the dynamic of the
errors that possibly occur from the current approach of bioavailability estimation. All the
parameter values used in the simulations to study the dose effect are summarized in
Table 3-1.
To further evaluate the influence of other TMDD parameters on the
bioavailability estimation of therapeutic proteins that undergo TMDD, the plasma
concentration-time profiles of filgrastim in the dose range of 0.01 ± 10 g/kg were
simulated with the variation of KD (0.001 ± 50 ng/mL), Kint (0.0001 ± 50 h-1), Koff (0.001
± 50 h-1), and Kon (0.001 ± 50 mL/ng·h). The respective parameter values and results for
these estimations are listed as supplemental data to this dissertation.
Data Analysis
Non-compartmental analysis was performed in Phoenix® WinNonlin 6.3 to
determine the area under the concentration-time curve (AUC) of the simulated profiles.
The absolute bioavailability estimation was calculated from Equation 3-17 under the
assumption of a dose-independent, constant clearance.
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Table 3-1.
Summary of the estimated population pharmacokinetic parameters of
filgrastim and denosumab following IV and SC administration that were used for
simulation to determine the dose effect on bioavailability estimation
Model drug
Filgrastim

Dose
0.01, 0.05,
0.1, 0.5, 1,
2.5, 5, 10,
50, 100,
500, 1000,
1500, 5000,
and 10000
g/kg

Denosumab

0.66, 1.98,
6, 6.6, 14,
15, 19.8, 30,
60, 66, 100,
120, 198,
and 210 mg

Parameters
F
Ka (h-1)
F2
D2
Ke (h-1)
Vd (L)
KD (ng/mL)
Kint (h-1)
Kdeg (h-1)
AR0 (g)
Koff (h-1)
Cs,0 (ng/mL)
F
Ka (d-1)
CLlin (mL/day/66 kg)a
V1 (mL/66 kg)
Q (mL/day/66 kg)a
V2 (mL/66 kg)
Kss (ng/mL)
Kint (d-1)a
Kdeg (d-1)a
R0 (ng/mL)

Fixed-effect estimate
0.691, 1.0
0.403
0.586
6.6
0.26
2.03
0.308
0.0438
0.215
12.7
0.389
0.0253
0.638
0.212
73.44
2490
909.6
1360
138
0.1908
0.03552
614

a

The parameter values were converted to day base unit. 66 kg is the typical weight of
postmenopausal women with osteoporosis in the original study [34].
NOTE: F = absolute bioavailability; Ka = first-order absorption rate constant; F2 =
bioavailability of the zero-order absorption process of filgrastim; D2 = duration of zeroorder absorption of filgrastim; Ke = first-order elimination rate constant; Vd = volume of

distribution of filgrastim; KD = equilibrium dissociation constant which equals to
;


Kint = first-order internalization rate constant; Kdeg = first-order degradation rate constant;
AR0 = pretreatment amount of G-CSF receptors in the blood and bone marrow; Koff =
first-order dissociation rate constant; Cs,0 = pretreatment concentration of G-CSF; CLlin =
linear clearance; V1 = central volume of distribution; Q = intercompartmental clearance;
V2 = peripheral volume of distribution; Kss = quasi-steady-state constant; R0 = baseline
RANKL level
Source: a) Wiczling, P., P. Lowe, E. Pigeolet, F. Ludicke, S. Balser, and W. Krzyzanski,
Population pharmacokinetic modelling of filgrastim in healthy adults following
intravenous and subcutaneous administrations. Clin Pharmacokinet, 2009. 48(12): p.
817-26.
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Table 3-1.

(Continued)

b) Sutjandra, L., R.D. Rodriguez, S. Doshi, M. Ma, M.C. Peterson, G.R. Jang, et al.,
Population pharmacokinetic meta-analysis of denosumab in healthy subjects and
postmenopausal women with osteopenia or osteoporosis. Clin Pharmacokinet, 2011.
50(12): p. 793-807.
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(Eq. 3-17)

where F is the absolute bioavailability, AUCSC is the AUC from SC administration,
AUCIV is the AUC from IV administration, DSC is the SC dose, and DIV is the IV dose. To
determine dose effect, F was calculated for the different combinations of doses after SC
and IV administration of filgrastim or denosumab. Dose normalized AUCs (AUC_D) and
average clearance (CL) at different doses were calculated to determine the effect of dose
on these parameters by using Equations 3-18 and 3-19 respectively.
 ܦ̴ܥܷܣൌ

 ܮܥൌ

ܥܷܣ

݁ݏܦ

 ܨή ݁ݏܦ

ܥܷܣ

(Eq. 3-18)

(Eq. 3-19)

To quantify the error in the bioavailability assessment, %prediction error was
calculated by Equation 3-20.
Ψܲ ݎݎݎ݁݊݅ݐܿ݅݀݁ݎൌ

ܨ௦ െ ܨ
 ൈ ͳͲͲ
ܨ

(Eq. 3-20)

where Fsim is the bioavailability calculated from the simulated data, and Fref is the
reference bioavailability which is the absolute bioavailability that was used to simulate
the plasma concentration-time profiles of filgrastim or denosumab. The reference values
are 0.691 or 1.0 for filgrastim, and 0.638 or 1.0 for denosumab.
Results
With reported population pharmacokinetic parameters and models for filgrastim
and denosumab, plasma concentration-time profiles at various IV and SC doses of both
protein drugs were simulated and shown in Figure 3-1. Notably, the pattern of plasma
concentration-time profile of both filgrastim and denosumab showed transition during
variation of IV and SC doses.
Subsequently, with the combinations of different IV and SC doses of filgrastim at
the reference bioavailability value of 0.691 (Fref = 0.691), the dose variation from 0.01 ±
10000 g/kg yielded the bioavailability estimations presented in Table 3-2. The absolute
bioavailability resulted from the dose effect varied from 0.172 ± 2.74 showing the
deviation from the reference bioavailability (Fref = 0.691) that was used for the drug input
in the TMDD model simulation. The corresponding prediction errors ranged from -75.1
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A
1000000

0.01mcg IV
0.01mcg SC
0.5mcg IV
0.5 mcg SC
2.5mcg IV
2.5mcg SC
5mcg IV
5mcg SC
10mcg IV
10mcg SC
10000mcg IV
10000mcg SC
Kd

100000
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Cp (ng/mL)

1000
100
10
1
0.1
0.01
0

20

40
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80
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Time (hr)
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140
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180

B
100000

0.66 mg IV

10000

0.66 SC

Cp
(ng/mL)

1000

1.98 mg IV

100

1.98 SC

10

6 mg IV

1

6 mg SC

0.1

30 mg IV

0.01

30 mg SC

0.001

210 mg IV

0.0001

210 SC

0.00001
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0.000001
0

50

100
Time (day)
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Figure 3-1. Simulated plasma concentration-time profiles of filgrastim and
denosumab after IV and SC administration
Plasma concentration-time profiles were simulated in the dose range of 0.01 ± 10000
g/kg for filgrastim (A) and 0.66 ± 210 mg for denosumab (B).
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Table 3-2.

Dose effect on the bioavailability estimation of filgrastim with reference bioavailability (Fref) equals to 0.691a

IV dose

SC dose (g/kg)

(g/kg)

0.01

0.01

0.683
(-1.11)
0.663
(-4.05)
0.627
(-9.29)
0.345
(-50.1)
0.261
(-62.3)
0.211
(-69.5)
0.194
(-72.0)
0.184
(-73.4)
0.175
(-74.6)
0.174
(-74.8)
0.173
(-75.0)
0.173
(-75.0)
0.172
(-75.0)
0.172
(-75.1)
0.172
(-75.1)

0.05
0.1
0.5
1
2.5
5
10
50
100
500
1000
1500
5000
10000

0.05

0.1

0.5

1

2.5

5

10

50

100

500

1000

1500

5000

10000

0.694
(0.462)
0.674
(-2.52)
0.637
(-7.85)
0.350
(-49.3)
0.265
(-61.7)
0.214
(-69.0)
0.197
(-71.5)
0.187
(-72.9)
0.178
(-74.2)
0.177
(-74.4)
0.175
(-74.6)
0.175
(-74.6)
0.175
(-74.6)
0.175
(-74.7)
0.175
(-74.7)

0.711
(2.91)
0.690
(-0.141)
0.652
(-5.60)
0.359
(-48.1)
0.271
(-60.7)
0.220
(-68.2)
0.201
(-70.8)
0.192
(-72.3)
0.182
(-73.6)
0.181
(-73.8)
0.180
(-74.0)
0.180
(-74.0)
0.179
(-74.0)
0.179
(-74.0)
0.179
(-74.0)

0.929
(34.4)
0.901
(30.4)
0.852
(23.3)
0.469
(-32.2)
0.355
(-48.7)
0.287
(-58.5)
0.263
(-61.9)
0.250
(-63.8)
0.238
(-65.5)
0.237
(-65.8)
0.235
(-66.0)
0.235
(-66.1)
0.234
(-66.1)
0.234
(-66.1)
0.234
(-66.1)

1.32
(91.7)
1.29
(86.0)
1.22
(75.8)
0.668
(-3.32)
0.506
(-26.8)
0.409
(-40.8)
0.375
(-45.7)
0.357
(-48.3)
0.340
(-50.8)
0.337
(-51.2)
0.335
(-51.5)
0.334
(-51.6)
0.334
(-51.6)
0.334
(-51.6)
0.334
(-51.7)

1.94
(180.)
1.88
(172)
1.78
(157)
0.977
(41.3)
0.739
(6.95)
0.598
(-13.5)
0.549
(-20.6)
0.522
(-24.5)
0.497
(-28.1)
0.493
(-28.7)
0.489
(-29.2)
0.489
(-29.2)
0.489
(-29.3)
0.488
(-29.3)
0.488
(-29.3)

2.26
(227)
2.19
(217)
2.07
(200.)
1.14
(64.7)
0.861
(24.7)
0.697
(0.851)
0.639
(-7.47)
0.608
(-12.0)
0.579
(-16.2)
0.575
(-16.9)
0.570
(-17.5)
0.570
(-17.5)
0.570
(-17.6)
0.569
(-17.6)
0.569
(-17.6)

2.46
(256)
2.39
(245)
2.26
(226)
1.24
(79.5)
0.938
(35.8)
0.759
(9.88)
0.697
(0.811)
0.663
(-4.12)
0.631
(-8.71)
0.626
(-9.41)
0.621
(-10.1)
0.621
(-10.2)
0.621
(-10.2)
0.620
(-10.2)
0.620
(-10.3)

2.67
(287)
2.59
(274)
2.44
(254)
1.34
(94.5)
1.02
(47.2)
0.823
(19.1)
0.755
(9.28)
0.718
(3.94)
0.684
(-1.04)
0.679
(-1.80)
0.674
(-2.51)
0.673
(-2.61)
0.673
(-2.65)
0.672
(-2.71)
0.672
(-2.72)

2.70
(290.)
2.62
(279)
2.48
(258)
1.36
(97.0)
1.03
(49.1)
0.833
(20.6)
0.765
(10.6)
0.727
(5.23)
0.692
(0.195)
0.687
(-0.579)
0.682
(-1.30)
0.681
(-1.40)
0.681
(-1.44)
0.681
(-1.50)
0.681
(-1.51)

2.73
(295)
2.65
(283)
2.50
(262)
1.38
(99.2)
1.04
(50.8)
0.843
(22.0)
0.773
(11.9)
0.735
(6.44)
0.700
(1.34)
0.695
(0.560)
0.690
(-0.166)
0.689
(-0.272)
0.689
(-0.310)
0.688
(-0.368)
0.688
(-0.382)

2.73
(296)
2.65
(284)
2.51
(263)
1.38
(99.5)
1.04
(51.0)
0.844
(22.2)
0.775
(12.1)
0.737
(6.62)
0.701
(1.51)
0.696
(0.731)
0.691
(0.00402)
0.690
(-0.103)
0.690
(-0.141)
0.690
(-0.199)
0.690
(-0.213)

2.74
(296)
2.65
(284)
2.51
(263)
1.38
(99.7)
1.04
(51.1)
0.845
(22.3)
0.775
(12.2)
0.737
(6.68)
0.702
(1.58)
0.696
(0.792)
0.691
(0.0642)
0.691
(-0.0427)
0.690
(-0.0808)
0.690
(-0.139)
0.690
(-0.153)

2.74
(296)
2.66
(284)
2.51
(263)
1.38
(99.9)
1.05
(51.3)
0.846
(22.4)
0.776
(12.3)
0.738
(6.78)
0.703
(1.67)
0.697
(0.883)
0.692
(0.155)
0.691
(0.0483)
0.691
(0.0101)
0.691
(-0.0481)
0.691
(-0.0620)

2.74
(296)
2.66
(285)
2.51
(264)
1.38
(99.9)
1.05
(51.3)
0.846
(22.4)
0.776
(12.3)
0.738
(6.80)
0.703
(1.69)
0.697
(0.905)
0.692
(0.177)
0.691
(0.0699)
0.691
(0.0317)
0.691
(-0.0265)
0.691
(-0.0404)

a

%Prediction errors are reported in the brackets. Bioavailabilities with minimum bias are reported in bold.
Light gray area demonstrates overestimated bioavailability with prediction error exceeds 20%.
Dark gray area demonstrates underestimated bioavailability with prediction error exceeds 20%.
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to +296. The overestimations tended to appear in the right upper area of the table when
high SC doses and low IV doses of filgrastim were used for bioavailability calculations;
whereas the underestimations of bioavailability were observed in the left lower area of
the table in which low SC doses and high IV doses of filgrastim were used for
bioavailability estimations. The acceptable prediction errors considered as ±20% were
attained when bioavailability was estimated from IV and SC filgrastim in the dose ranges
of 0.01 ± 0.1 g/kg and 5 ± 10000 g/kg irrespective of the combination of IV and SC
doses. The minimum biases tended to occur in the diagonal area of the table when the
similar doses of IV and SC filgrastim were used for the bioavailability estimation.
However, higher SC doses than IV doses were required in order to achieve the lowest
bias of bioavailability estimation except for IV dose of 0.1 g/kg that showed the
minimum error when it was paired with the same dose of SC administration. A similar
result was also observed when the input bioavailability for simulation was set to 1.0 (data
is shown in Table A-1 in the Appendix A section). However, the least deviation of
bioavailability estimation seemed to be mostly achieved with the same doses of IV and
SC administration when input bioavailability was set to 1.0.
Notably, even with the same doses of IV and SC filgrastim used for the
bioavailability assessment, some bias still occurred in the dose range of 0.01 ± 10 g/kg,
especially at 0.5 and 1 g/kg that showed a prediction error greater than 20% in the case
of input bioavailability was set to 0.691. In this dose range, the highest error of
bioavailability estimation occurred at 0.5 g/kg with prediction errors equaled to -32.2%
and -19.6% when Fref = 0.691 and Fref = 1.0 respectively (Figure 3-2).
Similarly to the full TMDD model for filgrastim, estimation of absolute
bioavailability for denosumab with the quasi-steady state approximation to the TMDD
model was also affected by dose variation. The results for dose variation from 0.66 ± 210
mg of IV and SC administered denosumab at Fref = 0.638 are shown in Table 3-3. The
absolute bioavailability varied from 0.0264 ± 12.5, substantial deviation from Fref =
0.638. The corresponding prediction errors ranged from -95.9 to +1862%. Most
overestimation was observed in the upper right corner of Table 3-3 when high SC and
low IV denosumab doses were used for bioavailability estimation; whereas the absolute
bioavailability was underestimated in the lower half left of Table 3-3 when low SC and
high IV doses were used for calculation. Bioavailability with acceptable prediction error
(± 20%) was estimated in the dose range of 60 ± 210 mg denosumab (lower right area of
the table) regardless of the combination of IV and SC doses. The least bias tended to be
presented along the diagonal area of the table when similar doses of IV and SC
denosumab with mostly higher SC doses than IV doses were used for bioavailability
estimation. Similar to filgrastim, simulation results of denosumab with Fref = 1.0 also
showed the same pattern and comparable magnitude of error (-95.5 ± 1926% prediction
error) as of those resulting from Fref = 0.638 (Table A-2 in Appendix A section).
Moreover, as in the case of filgrastim, the least deviation of bioavailability estimation
was achieved with mostly the same doses of IV and SC administered denosumab when
Fref = 1.0.
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filgrastim

%Prediction error of bioavailability estimation by dose effect in

32

Table 3-3.
0.638a

Dose effect on the bioavailability estimation of denosumab with the reference bioavailability (Fref) equals to
IV dose
(mg)
0.66
1.98
6
6.6
14
15
19.8
30
60
66
100
120
198
210

0.66
0.535
(-16.1)
0.256
(-59.8)
0.0750
(-88.2)
0.0693
(-89.1)
0.0439
(-93.1)
0.0426
(-93.3)
0.0383
(-94.0)
0.0339
(-94.7)
0.0297
(-95.3)
0.0293
(-95.4)
0.0279
(-95.6)
0.0274
(-95.7)
0.0265
(-95.9)
0.0264
(-95.9)

1.98
0.760
(19.1)
0.364
(-43.0)
0.107
(-83.3)
0.0984
(-84.6)
0.0624
(-90.2)
0.0605
(-90.5)
0.0544
(-91.5)
0.0482
(-92.4)
0.0421
(-93.4)
0.0416
(-93.5)
0.0396
(-93.8)
0.0390
(-93.9)
0.0375
(-94.1)
0.0374
(-94.1)

6
2.51
(294)
1.20
(88.5)
0.352
(-44.8)
0.325
(-49.0)
0.206
(-67.7)
0.200
(-68.6)
0.180
(-71.8)
0.159
(-75.0)
0.139
(-78.2)
0.137
(-78.5)
0.131
(-79.5)
0.129
(-79.8)
0.124
(-80.5)
0.124
(-80.6)

6.6
2.84
(344)
1.36
(113)
0.398
(-37.7)
0.367
(-42.4)
0.233
(-63.5)
0.226
(-64.6)
0.203
(-68.2)
0.180
(-71.8)
0.157
(-75.3)
0.155
(-75.7)
0.148
(-76.8)
0.145
(-77.2)
0.140
(-78.0)
0.140
(-78.1)

14
5.82
(812)
2.79
(337)
0.816
(27.8)
0.754
(18.1)
0.478
(-25.1)
0.463
(-27.4)
0.417
(-34.7)
0.369
(-42.2)
0.323
(-49.4)
0.318
(-50.1)
0.303
(-52.4)
0.298
(-53.2)
0.288
(-54.9)
0.286
(-55.1)

15
6.09
(855)
2.92
(357)
0.855
(33.9)
0.790
(23.8)
0.500
(-21.6)
0.486
(-23.9)
0.437
(-31.5)
0.387
(-39.4)
0.338
(-47.0)
0.334
(-47.7)
0.318
(-50.2)
0.313
(-51.0)
0.301
(-52.8)
0.300
(-53.0)

SC dose (mg)
19.8
30
7.17
8.63
(1024) (1252)
3.44
4.13
(438)
(548)
1.01
1.21
(57.7)
(89.6)
0.930
1.12
(45.7)
(75.2)
0.708
0.589
(-7.68) (11.0)
0.572
0.687
(-10.4) (7.74)
0.514
0.618
(-19.4) (-3.10)
0.455
0.547
(-28.7) (-14.2)
0.398
0.479
(-37.6) (-25.0)
0.393
0.472
(-38.4) (-26.0)
0.374
0.450
(-41.3) (-29.5)
0.368
0.443
(-42.3) (-30.6)
0.355
0.426
(-44.4) (-33.2)
0.353
0.425
(-44.6) (-33.4)

a

60
10.5
(1550)
5.04
(690.)
1.48
(131)
1.36
(114)
0.865
(35.5)
0.839
(31.5)
0.755
(18.3)
0.668
(4.70)
0.584
(-8.42)
0.576
(-9.65)
0.549
(-13.9)
0.540
(-15.4)
0.520
(-18.4)
0.519
(-18.7)

66
10.7
(1583)
5.14
(706)
1.51
(136)
1.39
(118)
0.882
(38.2)
0.856
(34.1)
0.770
(20.6)
0.681
(6.79)
0.596
(-6.59)
0.588
(-7.84)
0.560
(-12.2)
0.551
(-13.7)
0.531
(-16.8)
0.529
(-17.1)

100
11.5
(1707)
5.52
(766)
1.62
(153)
1.49
(134)
0.947
(48.4)
0.919
(44.0)
0.826
(29.5)
0.732
(14.7)
0.640
(0.287)
0.631
(-1.05)
0.602
(-5.72)
0.591
(-7.30)
0.570
(-10.7)
0.568
(-11.0)

120
11.8
(1752)
5.66
(787)
1.66
(160.)
1.53
(140.)
0.970
(52.1)
0.942
(47.6)
0.847
(32.7)
0.750
(17.5)
0.656
(2.78)
0.647
(1.41)
0.616
(-3.38)
0.606
(-4.99)
0.584
(-8.44)
0.582
(-8.77)

%Prediction errors are reported in the brackets. Bioavailabilities with minimum bias are reported in bold.
Light gray area demonstrates overestimated bioavailability with prediction error exceeds 20%.
Dark gray area demonstrates underestimated bioavailability with prediction error exceeds 20%.
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198
12.5
(1852)
5.96
(835)
1.75
(174)
1.61
(153)
1.02
(60.3)
0.992
(55.5)
0.892
(39.9)
0.790
(23.8)
0.691
(8.31)
0.682
(6.86)
0.650
(1.82)
0.639
(0.114)
0.616
(-3.52)
0.613
(-3.87)

210
12.5
(1862)
5.99
(839)
1.75
(175)
1.62
(154)
1.03
(61.1)
0.997
(56.3)
0.897
(40.6)
0.794
(24.4)
0.694
(8.85)
0.685
(7.40)
0.653
(2.33)
0.642
(0.620)
0.619
(-3.03)
0.616
(-3.38)

However, with the same doses of IV and SC denosumab, the bias of
bioavailability estimation was more pronounced than for filgrastim, especially in the case
of Fref = 0.638 as can be observed in Figure 3-3. At Fref = 0.638, a prediction error greater
than 20% was observed in the dose range of 1.98 ± 15 mg denosumab with the highest
bias occurring at 6 mg. In contrast to filgrastim that showed the bias peaks at the same
dose at different Fref, the most error occurred at 1.98 mg denosumab when Fref was set at
1.0.
The dose effect on dose-normalized AUC of filgrastim and denosumab were
investigated and shown in Figure 3-4. For filgrastim, at both Fref = 0.691 and Fref = 1.0,
dose-normalized AUC increased as the doses increased and exhibited the S-shaped curve
which could be observed in Figures 3-4A and 3-4B respectively. The rapid increase of
dose-normalized AUC occurred in the dose range of 0.1 ± 5 g/kg filgrastim. Similarly,
the same pattern of the dose effect on dose-normalized AUC were observed for
denosumab at both Fref = 0.638 (Figure 3-4C) and Fref = 1.0 (Figure 3-4D). The slightly
S-shaped curves showed an increasing of dose-normalized AUC as the doses increased in
the range of 0.66 ± 210 mg. The sharp increase of dose-normalized AUC occurred at the
dose of 1.98 mg onward and seemed to reach a plateau at very high dose. Notably, dosenormalized AUC tended to level off at 60 mg IV and SC doses of denosumab.
The alteration of dose-normalized AUC during dose variation may imply the
disproportional change in filgrastim and denosumab plasma concentrations at different
doses resulted from the concentration-dependent clearance. The dynamic of clearance
alteration at different doses was subsequently investigated and the results are shown in
Figures 3-5 and 3-6 for filgrastim and denosumab, respectively. Dose effect on clearance
was linked by a peak plasma concentration (Cmax) since the rate of elimination depends
on available systemic concentration.
Upon increasing dose, Cmax after IV and SC administration was increased.
However, the increasing pattern of Cmax after SC administration was slightly different
from what was observed after IV administration with the extra reflection points in the
dose range of 0.1 ± 5 g/kg for filgrastim (Figure 3-5A) and below 60 mg for denosumab
(Figure 3-6A). Different degrees of clearance at various IV and SC doses of filgrastim
and denosumab were subsequently correlated with the corresponding Cmax. To truly
represent clearance for protein drugs that undergo TMDD at various doses, average
clearance determined from plasma concentration-time profiles after IV administration
was used as a reference.
Due to the wrong assumption of dose-independent clearance that was used for
bioavailability estimation for protein drugs that undergo TMDD, average clearances that
were determined from plasma concentration-time profiles of SC administration showed
bias with the deviation from average clearance after IV administration (Figures 3-5B and
3-6B for filgrastim and denosumab, respectively). F that was used in the calculation for
determining the average clearance after SC administration (Equation 3-19) only
accounted for bias within apparent clearance that associated with dose- independent
elimination. Thus, average clearance determined from concentration-time profile after SC
34
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Figure 3-4. Dose effect on the dose normalized AUC of filgrastim and denosumab
The effect of dose on dose-normalized AUC of filgrastim exhibited an S-shaped curve
with dose normalized AUC increased as dose increased in the range of 0.1 ± 10 g/kg at
both F = 0.691 (A) and F = 1.0 (B). Similarly, the effect of dose on dose-normalized
AUC of denosumab showed a slightly S-shaped curve with dose normalized AUC
increased as dose increased in the range of 0.66 ± 210 mg at both F = 0.638 (C) and F =
1.0 (D).
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Figure 3-5. The correlation between dose and average clearance of filgrastim
through the alteration of plasma concentration
Due to increasing dose, peak plasma concentration of IV and SC administered filgrastim
(Cmax) was increased (A). At various Cmax, different degrees of clearance were observed
(B).
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Figure 3-6. The correlation between dose and average clearance of denosumab
through the alteration of plasma concentration
Due to increasing dose, peak plasma concentration of IV and SC administered
denosumab (Cmax) was increased (A). At various Cmax, different degrees of clearance
were observed (B).
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administration may warrant at very low or very high doses when linear elimination
process was dominated.
For filgrastim, clearance showed a perfect S-shaped correlation to the various
degree of Cmax with a high degree of constant clearance at low Cmax and low invariant
clearance at high Cmax (Figure 3-5B). It should be noted that a very active dynamic in the
alteration of clearance occurred in the plasma concentration range corresponding to 0.1 ±
5 g/kg filgrastim regardless of administration route. In contrast to filgrastim, clearance
of denosumab did not show an S-shaped pattern (Figure 3-6B). However, similar to
filgrastim, minimum constant clearance was achieved at the high dose. A dynamic
change in clearance of denosumab was observed in the plasma concentration range that
was corresponded to doses lower than 60 mg for both IV and SC administration.

Discussion
With dose-dependent clearance and subsequent non-linear pharmacokinetics,
bioavailability estimations are difficult to perform for drugs that undergo a TMDD
process since the standard methodology for bioavailability estimation is calculated under
the assumption of dose-independent, constant clearance. As a consequence of an
assumption violation, the dose-dependent bioavailability that is usually observed when
the standard methodology is used in drugs that exhibit TMDD pharmacokinetics is
misleading. This notion is supported by this simulation study when the bioavailability of
filgrastim and denosumab were determined at various doses.
Although, the assumption and limitation of pharmacokinetic models can impact
the simulated concentration-time profiles [41] in which they might deviate from the real
pharmacokinetic profiles, the full TMDD model and the quasi-steady-state approximation
of the TMDD model that were proven to adequately describe the pharmacokinetics of
filgrastim [42] and denosumab [34], respectively, should be able to fairly reproduce the
pharmacokinetic profiles of both protein drugs. Transition in the characteristics of plasma
concentration-time profiles of filgrastim and denosumab during variation of doses is also
observed in a study of the dynamics of TMDD by Peletier and Gabrielsson [41]. The
nonlinear pharmacokinetics and dose-dependent bioavailability that were observed in
both therapeutic proteins in this study have also been reported in other studies [33] and
for several other protein drugs that undergo TMDD [29, 31].
Dose-dependent bioavailability that was observed in filgrastim and denosumab
was a result from a change in dose-normalized AUC during dose alteration. Regardless of
the assumed nominal bioavailability Fref and the applied pharmacokinetic model, the dose
had an effect on the dose normalized AUC of both therapeutic proteins, filgrastim, and
denosumab. As doses increased, the dose-normalized AUCs tended to increase which
were very obvious in the dose range of 0.1 ± 5 g/kg for filgrastim and 1.98 mg onward
for denosumab. This dose effect on the dose normalized AUC was also observed in
population pharmacokinetic-pharmacodynamic modeling of filgrastim in healthy
volunteers [33] and during a population pharmacokinetic study of AMG 317, a fully
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human monoclonal antibody against IL4 receptor [45] in which the increasing dose
caused an increase in dose-normalized AUC during non-compartmental analysis.
The increment in dose-normalized AUC upon increasing dose of filgrastim and
denosumab may indicate a disproportionate increase in plasma concentration, which may
subsequently imply the alteration in clearance due to the variation of dose. The results
showed that different degrees of clearance could be observed at various plasma
concentrations (Cmax) resulting from different IV doses of filgrastim and denosumab. The
cooperation between two elimination pathways, a linear clearance and a target receptormediated elimination, may impart the dynamic in the alteration of clearance during dose
variation. Similar to what is described in the dynamics of TMDD study [41], different
plasma concentrations of ligand determine which elimination pathway becomes
predominant. At low plasma concentration (low dose) of protein drugs, target receptors
still have the capacity for the elimination of ligands, thus TMDD is considered as the
main pathway of clearance. However, increasing plasma concentration upon increasing
dose until target receptor becomes partially saturated, the contribution of TMDD to the
overall clearance may decrease and protein drugs are more potentially eliminated via a
linear clearance pathway. After all target receptors are saturated at very high plasma
concentration (high dose) of therapeutic proteins, the linear clearance pathway is
dominated. The transition between these two elimination pathways during dose variation
may not only cause a change in the degree of clearance but also influence the transition in
the characteristics of plasma concentration-time profile as could be observed in filgrastim
and denosumab.
For both protein drugs, the average clearance tended to decrease as plasma
concentration increased and this decreasing was very obvious in the corresponding dose
range of 0.1 ± 5 g/kg for filgrastim and below 60 mg for denosumab. The dosedependent or concentration-dependent clearance observed in this study was also observed
in interferon-E1a [31], other several therapeutic monoclonal antibodies [29] such as
tocilizumab [46], PF-04840082 (Dickkopt-1 antibody) [47], panitumumab, cetuximab
[32], and concizumab [48], a bivalent humanized nanobody [49], and in the study of the
dynamics of TMDD [40]. At very high doses of both protein drugs, the clearance reached
the lowest plateau phase, which might be due to the saturation of the targets that are
responsible for protein degradation. At this plateau phase after high dosing, the linear
clearance pathway becomes predominant [29, 31, 32, 34, 40, 46, 48].
As a consequence of transition between two elimination pathways, change in the
degree of clearance, and transition in the characteristics of plasma concentration-time
profile, disproportional increased AUC upon increasing dose may contribute to the
increment of dose-normalized AUC. Due to these artifacts, if different IV and SC dose
levels are combined and used for bioavailability estimation, it may cause bias. The results
showed the overestimation of bioavailability was observed with the combination of high
SC doses and low IV doses, and the underestimation of bioavailability occurred when the
combination of low SC doses and high IV doses was used.
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In the original clinical study, the bioavailability of filgrastim was determined from
three SC injections of 2.5, 5, and 10 g/kg, and one IV infusion of 5g/kg over half an
hour. However, according to the results reported in Table 3-2, bioavailability estimation
within this dose range could result in prediction error ranging from -20.6% to +0.811%.
For denosumab, pooled data from 11 clinical studies with IV and SC dose range of 6 ±
210 mg possibly resulted in the bias of bioavailability estimation in the range of -80.6 ±
+175% (Table 3-3). Thus, the bioavailability obtained for filgrastim and denosumab may
not represent the true bioavailability.
However, the bioavailability of filgrastim and denosumab could be estimated with
±20% prediction error if the assessment was performed in the dose ranges of 0.01 ± 0.1
g/kg or 5 ± 10000 g/kg for filgrastim, and 60 ± 210 mg for denosumab. Notably, any
combination within these dose ranges could be used for bioavailability estimation.
Interestingly, these dose ranges yielded constant dose normalized AUC. The constant
dose-normalized AUC might result from a proportional increase in plasma concentration
which was due to the concentration-independent clearance that concurrently occurred
within these dose ranges. To minimize the bias of bioavailability estimation, similar or
the same doses of IV and SC administration should be used. It should be noted that if Fref
was less than 1.0, slightly higher SC dose than IV dose should be combined in order to
attain the least deviation. This may imply that similar plasma concentration after IV and
SC administration may be required in order to achieve the minimum bias. It seems
intuitively possible since similar plasma concentration after IV and SC administration
may be eliminated with a similar degree through the same pathway of clearance.
Nevertheless, with the same IV and SC doses, prediction error greater than 20% still
occurred when bioavailability estimations were calculated in the dose range of 0.5 ± 1
g/kg filgrastim and 1.98 ± 15 mg denosumab. The errors that occurred when
bioavailability was estimated from an equal dose of IV and SC administration might
result from other factors that affect the clearance of drugs that go through TMDD
pathway which in turn can affect the drug concentration-time profiles and AUCs.
Other factors that possibly have an impact on the bioavailability assessments of
drugs that undergo TMDD are the parameters specific for the TMDD process, the
dissociation rate constant (KD) which describes the binding (Kon) and dissociation (Koff)
processes, and the internalization process described by Kint that occurs after drugs bind to
their receptors. Moreover, for denosumab, the quasi-steady-state constant (Kss) in the
quasi-steady-state approximation to TMDD model can be an influential factor. The
effects of all these parameters were shown to affect the drug concentration vs time
profiles in the dynamics of TMDD study dependent on the dose of the ligands [40, 41].
The impact of these factors was further explored in the supplemental material.
It should be noted that the bioavailability of therapeutic proteins that follow a
TMDD pathway should be carefully estimated, especially in the dose range in which the
target sites are partially saturated and both elimination pathways have equal potential to
contribute to the overall clearance, since dose-normalized AUC varies actively with dose
at this state. To overcome this problem, a very low dose of protein drug within the
capacity of target receptor can be used for bioavailability assessment. However, with the
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limitation of the sensitivity of the analytical method, this may become problematic.
Another solution is to perform bioavailability estimation at the high dose of therapeutic
proteins that saturate all target sites and render the linear clearance pathway to become
dominant. At this state, the bioavailability estimation is no longer dependent on dose.
Thus, this saturation phase should be the suitable state for determining the true absolute
bioavailability with the least bias. In many instances, however, these are supratherapeutic doses that cannot practically administer to human subjects or animal.
Ideally, to get an accurate assessment of bioavailability of protein drugs that
undergo TMDD, the IV doses should be administered at the amounts that will generate
the exact same plasma concentration-time profiles as those from SC administrations.
However, this might be difficult to accomplish since carefully monitoring the drug
plasma concentration-time profile is required during IV infusion. Even in an ideal
scenario in which nonlinearity through TMDD can be overcome by high doses (as
outlined in the previous chapter), other factors can affect the bioavailability assessment of
therapeutic proteins. One such factor that could result in true nonlinearity in
bioavailability is the absorption process that occurs in the body. In a study by Zhao et al.,
bioavailability is shown to be sensitive and negatively related to transit time for the drug
from lymph system to systemic circulation (W) and elimination rate during lymphatic
transport (Klymph) [50]. Moreover, bioavailability is also found to be sensitive and
positively related to the lymphatic flow rate when the lymphatic flow rate is set to less
than 0.5 fold of original value.
Gibiansky et al suggest another way to determine the absolute bioavailability with
a minimum bias for drugs that exhibit nonlinear pharmacokinetics , in which the ratio of
IV and SC doses that provided equal AUCs are used for bioavailability estimation [51].
By this method, the approximation underestimates the true bioavailability by no more
than 5 ± 30% with more precision of approximation achieved when AUC at steady-state
is used for calculation. Moreover, the bias decreases with the increase of SC absorption,
true bioavailability, and SC dose. This finding may also imply that equal amount of
protein drugs presented in the systemic circulation after IV and SC administration is
required in order to achieve a minimum bias of bioavailability estimation. According to
this finding, the bioavailability of filgrastim and denosumab may be more accurately
estimated by determining the ratio of IV and SC doses that possessed equal AUCs.
In conclusion, with the current methodology and assumptions of bioavailability
determination, the absolute bioavailability of drugs that undergo a TMDD pathway and
exhibit nonlinear pharmacokinetics are estimated with bias. The bias is caused by a dose
effect on the dose-normalized AUC, which is the result of concentration-dependent
differences in clearance based on differences in the characteristics of the concentrationtime profiles. To achieve more accurate bioavailability estimation, the absolute
bioavailability should be determined, if possible, at low or high doses when the invariant
clearance is observed or with the alternate estimation method suggested by Gibiansky et
al [51]that determines the ratio of IV and SC doses that generate equal AUCs.
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CHAPTER 4.

THE ONTOGENY OF NEONATAL FC RECEPTOR (FCRN)
EXPRESSION IN MICE
Introduction

The neonatal Fc receptor (FcRn) (reviewed in [16, 52-56]), also known as the
Brambell receptor, is a major histocompatibility (MHC) class I-like molecule that is
encoded by Fcgrt. It is a heterodimeric glycoprotein consisting of one heavy chain with a
large extracellular part associated with one E2 microglobulin (E2m) subunit followed by a
transmembrane segment and a short cytoplasmic tail. The extracellular part of the FcRn
heavy chain is composed of three subunits denoted as D1, D2, and D3 (Figure 4-1). The
functions of FcRn include protection of IgG and albumin from catabolism, transportation
of IgG across epithelial cells, and antigen presentation in immunoprotective systems.
IgGs and albumins are found to bind noncompetitively and without cooperativity to the
distinct FcRn binding site. Although FcRn can bind to IgG as a 1:1 complex, most studies
have shown that two FcRn molecules bind to a single IgG with the stoichiometric ratio of
2:1 [52, 53, 55]. Mutational and crystallographic studies have revealed the Fc-FcRn
complex structure, and proposed that FcRn uses the C-terminal portion of the D2 domain,
the first residue of E2-microglobulin and carbohydrate to interact with the Fc CH2-CH3
interface [57, 58]. Upon the pH-dependent binding process, FcRn does not undergo a
major conformational change. However, a slight rearrangement of the FcRn side chain
and chemical alteration of the amino acid residues occurs at the binding interface.
As previously described in Chapter 1, FcRn resides mainly within acidic
cytoplasmic vesicles inside the cells. The interaction with IgG is initiated when
circulating IgG is taken up by receptor-mediated endocytosis or fluid-phase pinocytosis,
and subsequently binds to FcRn in the endosomes (Figure 1-2). The acidic environment
causes protonation of the histidine residues in the area between the CH2 and CH3 domains
of the Fc region. The protonated histidine binds to the binding site on the FcRn heavy
chain. After binding the IgG-FcRn complex returns to the apical or basolateral side of the
cell surface membrane in the recycling and transcytosis processes, respectively. The
exposure to physiological pH causes the release of IgG to the blood stream or the
extracellular fluid. This process occurs in a strictly pH-dependent manner such that the
binding takes place in an acidic environment (a 6.0 ± 6.5) and the release takes place in
the physiological or neutral milieu (a 7.4) [59-65]. This pH dependencyis the
consequence of the presence of the conserved histidine residues on the Fc fragment of
IgG that bind to the D2 domain of FcRn [52].
FcRn expression has been detected in a variety of endothelial, epithelial, and
hematopoietic cells in various organs throughout the body, including skin [64, 66, 67],
muscle [66, 68], liver [63, 68-70], kidney [66, 71], spleen [66, 70], lung [70, 72],
mammary gland [73], intestine [62, 66, 69, 70, 72, 74-79], stomach [69], brain [66, 80,
81], eye [82], immune cells [65, 83], and placenta [84-87] (Table 4-1). FcRn is expressed
throughout life and differs across tissue types and species. However, a developmental
downregulation of intestinal FcRn mRNA and protein are observed in adult rodents
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Figure 4-1. The crystal structures of human FcRn and rat FcRn-rat IgG Fc
complex
(A) The crystal structure of human FcRn. The loci of the amino acids essential for IgG
(E115, E116, D130, W131, L135 and I1) and albumin (H166) binding are highlighted.
(B) The co-crystal structure of rat FcRn with a rat IgG Fc fragment. The amino acid
residues (H310, H435, and I253) at the Fc elbow region involved in binding to FcRn are
highlighted with numbers and arrows. The glycosylated amino acid residue N297 in the
CH2 domain of rat Fc is shown as a red spherical ball and numbered. The corresponding
amino acid residues on rat FcRn involved in IgG Fc (E117, E118, E132, W133, D137,
and I1) and albumin binding (H168) are indicated as red balls. In both figures, the FcRn
heavy chain is shown in green and E2m in orange.
Source: Reprinted with permission from The Japanese Society for the Study of
Xenobiotics (JSSX). Andersen, J.T. and I. Sandlie, The versatile MHC class I-related
FcRn protects IgG and albumin from degradation: implications for development of new
diagnostics and therapeutics. Drug Metab Pharmacokinet, 2009. 24(4): p. 318-32.
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Table 4-1.
Organs
Skin

Liver

Kidney

Lung

Intestine

Distribution of FcRn expression in various organs and their functions
Cell types and tissues
Endothelial cell
- Capillary endothelium [66]
Epithelial cell
- Stratum corneum, keratinocytes,
melanocytes, sebaceous glands, and hair
follicles [64, 67]
Hematopoietic cell
- Histiocytes
Endothelial cell
- Capillary endothelium [68]
Epithelial cell
- Hepatocyte [63, 66, 70], sinusoidal and
canalicular membranes [63, 66, 68, 69]
Hematopoietic cell
- Kupffer cells [66, 69]
Epithelial cell
- Podocytes, and proximal tubule cells
[66, 71]
Epithelial cell
- Apical regions of large and small
bronchiolar airways, and alveolar [72]
Hematopoietic cell
- Macrophages [66]
Epithelial cell
- Apical membranes of enterocyte villi,
and crypts of small intestine [66, 75-79]
Hematopoietic cell
- Macrophages in intestinal lamina propria
[65, 69, 77]

Muscle

Endothelial cell
- Capillary endothelium [66, 68, 69]
Epithelial cell
- Endomysium [68]

Stomach

Epithelial cell
- Gastric mucosa [69]
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Functions
- Homeostasis of IgG [68]

- Recycling of IgG [88]

- Recycling of IgG to
prevent accumulation in
the kidney
-Absorption of IgG and Fc
fusion proteins [72]
- Antigen presentation
process
- Absorption of IgG and
Fc-fusion proteins
- Antigen presentation
process

Table 4-1.
Organs
Spleen

Eye

Central
nervous
systems

(Continued)
Cell types and tissues
Endothelial cell
- Capillary endothelium [89]
Hematopoietic cell
- Macrophages [66, 89]
Endothelial cell
- Capillary endothelium [82]
- Corneal endothelium [82]
Epithelial cell
- Corneal, conjunctiva, non-pigmented
ciliary, optic nerve, and lens epithelium
[82]
Endothelial cell
- Capillary endothelium [66, 80, 81]
Epithelial cell
- Choroid plexus ependymal cells, and
peripheral nerve perineurium [66, 80]

Reproductive Endothelial cell
organs
- Placental endothelial cells [84]
(inconsistently detected)
Epithelial cell
- Mucosa of uterine and vaginal tissues
- Syncytiotrophoblasts of placenta [85,
87]
Mammary
organs

Epithelial cell
- Acinar epithelium of mammary glands
[73]

Blood

Hematopoietic cell
- Monocytes, monocyte-derived dendritic
cells, and polymorphonuclear neutrophils
(PMN) [65, 83, 89]
- B cells [89](inconsistently detected)

Lymph node

Hematopoietic cell
- Macrophages, and dendritic cells [66]
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Functions

- Antigen presentation
process
- Blood-ocular barrier [82]

- Efflux of IgG from the
brain to blood [81]

- Maternofetal immunity
transfer

- Maternofetal immunity
transfer in rodent
(Recycling of IgG)
- Recycling of IgG during
homeostasis
- Antigen presentation
process
- Antigen presentation
process

relative to neonates [62, 74-76]. In the rat, reduction in FcRn mRNA and protein
expression occurs in an age-dependent manner in the distal to proximal direction until
FcRn-mediated IgG absorption is no longer detected at 3 weeks postpartum. Moreover,
an upregulation of the expression of FcRn protein has been shown in mouse brain
microvessels during aging [81]. These data suggest age-dependent differences in FcRn
expression at different stages of development which might impact the pharmacokinetics
of therapeutic proteins that bind to this receptor. To investigate the effect of ontogeny on
the FcRn, FcRn protein expression in different organs was quantified relative to GAPDH
expression, in different age groups of C57BL/6J mice in this study.
Due to preliminary results (data not shown) and information from the literature
showing that expression of FcRn in adult rodent intestine [74, 75, 79], and stomach [66,
74] were undetectable, along with the low probability that these organs are involved in
the homeostasis of therapeutic proteins that bind to this receptor, FcRn expression was
not quantitated in these organs. Moreover, IgG is found to preferentially distribute to the
lung, kidney, spleen, liver, and skin [55]. Thus, relative FcRn expression was quantified
in these organs in 2, 10, 21, 42, and 70 day old animals. Although studies in adult mice
reveal that FcRn is expressed in a functionally active form in the endothelium of small
arterioles and capillaries of skin, muscle, liver, adipose tissues [68], and hematopoietic
cells [66, 89], the potential of functional FcRn in other organs of neonates could not be
precluded.
Materials and Methods
Animals
In order to obtain at least six animals at different ages including 2, 10, 21, 42, and
70 days of age, nine timed-pregnant C57BL/6J mice were purchased from The Jackson
Laboratory (Bar Harbor, ME). Animals were shipped at 7 - 15 days of gestation and
arrived at 10 - 18 days of gestation. All timed-pregnant mice were housed in the animal
facility for 1 week before the delivery with free access to food and water. Pups delivered
by pregnant mice were raised to pre-determined ages according to the study design and
weaned at day 21. The day of birth was assigned as the first day of life (day 1). Males and
females were housed separately in different cages at the weaning age (day 21) with ear
tags for background tracking. All animals were housed in standard laboratory cages and
had free access to food and water throughout the study period.
Organ Collection
At least one offspring from each timed-pregnant C57BL/6J mice was sacrificed
for tissue collection at ages 2, 10, 21, 42, and 70 days. Each age group contained at least
six animals, both males, and females. Euthanasia was performed with CO2 and cervical
dislocation in all age groups except mice at ages 2 and 10 days, which were sacrificed by
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decapitation. The animal protocol was approved by the Institutional Animal Care and Use
Committee (IACUC) at the University of Tennessee Health Science Center. All organs
including skin, liver, kidneys, lung, spleen, heart, stomach, intestine, and pancreas were
collected and preserved on ice. Blood was removed from all the organs using ice-cold
phosphate-buffered saline (PBS). All organs were subsequently stored at -70qC until
further processing.
Tissue Lysate and Total Protein Extract Preparation
Total protein extract from each organ was prepared using a commercial total
protein extraction kit (Millipore, Billerica, MA). A 20 ± 40-mg sample of tissue was
excised from the whole organ and chopped into very small pieces. The tissue was then
added into Eppendorf tubes containing 1×PI (a cocktail of protease inhibitor) in TM
buffer (mixture of HEPES (pH 7.9), MgCl2, KCl, EDTA, sucrose, glycerol, sodium
deoxycholate, NP-40, sodium ortho-vanadate) at a gram of tissue per 2.5 mL solution,
and were kept on ice for at least 5 minutes. The tissue was subsequently homogenized
using a micro-homogenizer (Bio-Gen PRO200 model from Pro Scientific, Oxford, CT) at
a minimum speed of 3 - 5 cycles of alternate homogenizing and resting on ice to
minimize protein destruction. The tissue homogenate was rotated at 4qC for 20 minutes.
Subsequently, the tissue lysate was centrifuged at 11,000 rpm at 4qC for 20 minutes. The
supernatant was subsequently collected and stored at -20qC for further analysis.
Protein Quantification
Total protein in the supernatant from all samples was quantified by using the
BCA protein assay kit (Novagen®, Billerica, MA). Different concentrations (0 ± 1000
g/mL) of bovine serum albumin (BSA) were prepared for a calibration curve. 25 L of
each BSA standard and protein sample were mixed with 200 L BCA working reagent (a
mixture of BCA solution and 4% cupric sulfate) on a 96-well plate. The mixture was then
incubated at 60qC for 15 minutes before cooling to room temperature. The absorbance at
562 nm was measured on a plate reader (Beckman Coulter DTX880). The protein amount
in the samples was determined based on the calibration curve of BSA.
Electrophoresis
Proteins in the isolated extracts were separated by gel electrophoresis. The
electrophoresis was run for 90 minutes on ice in an XCell SureLockTM Mini-Cell
(Invitrogen, Carlsbad, CA) system containing NUPAGE® MOPS SDS running buffer
(Invitrogen, Carlsbad, CA) and 500 L of NUPAGE® antioxidant (Invitrogen, Carlsbad,
CA). The samples loaded on each gel comprise the following:
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- Protein molecular weight markers: 5 L of MagicMarkTM XP (Invitrogen,
Carlsbad, CA) + 5 L of Novex® Sharp pre-stained protein standards
(Invitrogen, Carlsbad, CA)
- Positive control: 25 ng of recombinant mouse FcRn (R&D Systems) + 1.5 L of
10× NUPAGE® sample reducing agent (Invitrogen) + 3.75 L of 4× NUPAGE®
LDS sample buffer (Invitrogen)
- Negative control: 18 g of bovine serum albumin + 1.5 L of 10× NUPAGE®
sample reducing agent (Invitrogen) + 3.75 L of 4× NUPAGE® LDS sample
buffer (Invitrogen)
- Unknown specimens: 20 and 40 g of total protein extract from each organ in
each age group + 1.5 L of 10× NUPAGE® sample reducing agent (Invitrogen,
Carlsbad, CA) + 3.75 L of 4× NUPAGE® LDS sample buffer (Invitrogen,
Carlsbad, CA)
The positive control, negative control, and unknown specimens were heated in a
water bath at 70qC for 10 minutes before loading into 4 ± 12% NUPAGE® bis-tris gels
(Invitrogen, Carlsbad, CA). The electrophoresis condition was set to 150 V constant
voltage with maximum current of 0.13 A.
Western Blot
After electrophoresis, separated proteins were transferred for 2 hours 15 minutes
onto an Immobilon®-FL polyvinylidene fluoride (PVDF) 0.45 m membrane (EMD
Millipore, Billerica, MA) at 25 V and 0.17 A. The PVDF membrane was first pre-wetted
in methanol for 1 minute and then rinsed with ultra-purified water followed by soaking in
a mixture of NUPAGE® transfer buffer (Invitrogen, Carlsbad, CA) containing 20%
methanol and NUPAGE® antioxidant (Invitrogen, Carlsbad, CA). The transfer process
was run on ice in the XCell IITM Blot Module (Invitrogen, Carlsbad, CA) system that
contained a mixture of NUPAGE® transfer buffer that was used to equilibrate the PVDF
membrane.
The protein-transferred PVDF membrane was re-wetted for 1 minute in methanol,
rinsed with ultra-purified water, and soaked in 1×PBS for 2 minutes. To prevent
nonspecific binding of primary antibodies, the membrane was incubated in the Odyssey®
blocking buffer (LI-COR, Lincoln, NE) for 1 hour at room temperature. An overnight
incubation at 4qC was subsequently carried out in a mixture of 1:2000 goat anti-mouse
FcRn polyclonal antibody (R&D Systems, Minneapolis, MN) and 1:10000 rabbit antimouse GAPDH monoclonal antibody (Cell Signaling, Beverly, MA) that was prepared in
the Odyssey® blocking buffer containing 0.2%Tween 20. Protein transferred PVDF
membrane was then rinsed and washed with 0.1% Tween 20 in PBS for four times,five
minutes each. The incubation with a mixture of secondary antibodies in Odyssey®
blocking buffer containing 0.2% Tween 20 and 0.01% sodium dodecyl sulfate (SDS) was
subsequently performed for 1 hour at room temperature under light protection. The
secondary antibodies in a mixture comprised 1:15000 donkey anti-goat IRDye® 800CW
IgG (LI-COR, Lincoln, NE) and 1:15000 donkey anti-rabbit IRDye® 680RD IgG (LI49

COR, Lincoln, NE). After the incubation, rinsing and 5 minutes washing of the blot were
completed for 4 times prior to rinsing with 1×PBS. Protein bands on the blot were
detected and the intensity quantified by the Odyssey®Sa Infrared Imaging System (LICOR, Lincoln, NE).
Data Analysis
FcRn expression was determined by the relative intensity of GAPDH band in the
same sample. Within each individual sample set (20 and 40 g loading), average relative
expression of FcRn in each organ was compared across age groups by analysis of
covariance (ANCOVA). Multiple comparisons with Bonferroni adjustment were
performed to determine the difference of relative FcRn expression during development.
Statistical analysis was performed in SAS 9.3 (SAS Institute Inc.). The difference in the
relative FcRn expression between males and females in each age group was evaluated by
t-test with unequal sample size.
Results
Relative FcRn protein expression in mouse organs was quantified by
normalization of FcRn expression to the expression of the reference protein GAPDH
within the same sample. The relative expression of FcRn protein was compared across 2,
10, 21, 42, and 70 day old mice. The Western blot scans of FcRn and GAPDH protein
expression in mouse skin, liver, kidney, lung, and spleen from two sample sets (20 g
and 40 g loading) are shown in Figure 4-2. The rationale for using two protein loading
amounts was to assure that FcRn could be detected and quantified across all age groups
since analytical sensitivity might be a problem with the down-regulation of FcRn.
However, the results revealed that detection sensitivity was not an issue and FcRn in all
age groups could be detected and quantified in both sample sets. Nevertheless, due to the
limitations of protein abundance and the size of the organ, the 40-g loading amount
could not be performed in spleen samples from 2 day old mice.
Under reducing conditions of electrophoresis, native FcRn proteins in mouse
tissues were detected at 45 ± 55 kDa whereas recombinant mouse FcRn, a positive
control, was consistently detected at a molecular weight a 45 ± 47 kDa. This observation
could be explained by the fact that the recombinant protein was synthesized as Ser22 ±
Val301 with no attached E2m subunit. Moreover, additional modifications, such as a Cterminal 6-His tag, may contribute to the observed difference in the molecular weight. In
contrast to other mouse organs, the Western blot scans showed double bands of FcRn
protein at 45 ± 55 kDa in mouse liver samples (Figure 4-2B). Broad bands of FcRn were
observed in the range of 45 ± 55 kDa in some samples, especially those from liver and
kidney. In addition, an extra band at the molecular weight a 140 - 150 kDa was always
present in mouse liver samples, which may be the result of the complex formation of
FcRn monomers. Alternatively, cross-reactivity of the primary antibody with another
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Figure 4-2. Western blot scan of FcRn and GAPDH protein expression in mouse
skin (A), liver (B), kidney (C), lung (D), and spleen (E).
FcRn expression was quantified relative to GAPDH expression. The expression of FcRn
was compared across all age groups within each loading sample set (20 g and 40 g
loading amount) in each organ.
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protein might have occurred. Due to this uncertainty, the relative expression of FcRn
protein in mouse liver was quantitated based on the FcRn monomer at molecular weight
45 - 55 kDa and compared across all age groups.
Since there was no limitation of analytical sensitivity from loading protein at 20
g but the scarcity of protein abundant arose from loading protein at 40 g of spleen
sample obtained from 2 day old mice, the results focused on the 20-g loading sample
set. The quantitation results of FcRn protein relative to GAPDH protein expression from
the 20-g loading samples are presented in Figures 4-3 to 4-7 while the results of the 40g loading compared to those of the 20-g loading are available in the Appendix B
section (Figures B-1 to B-5). Notably, there was a statistically significant difference
between the relative amounts of FcRn protein expression in the 20-g and 40-g loading
sample sets (p < 0.05). The relative FcRn expression was consistently higher in the 40-g
loading sample set than in the 20-g loading sample set. Nevertheless, FcRn expression
across all age groups showed the same pattern between two loading sample sets. As a
result, the relative FcRn protein expression was compared among all age groups within
each loading sample set.
In mouse skin, relative FcRn protein expression was not different among the
investigated age groups, although the power to detect a difference was diminished due to
lower than expected animal numbers in three age groups (Figure 4-3).
In mouse spleen (Figure 4-7), relative FcRn protein expression was also not
statistically significantly different among the investigated age groups. Notably, the high
variation observed in the relative FcRn protein expressions obtained from day 2 and day
10 animals may hinder the detection of significant difference.
In mouse liver; however, the relative FcRn protein expression significantly
increased approximately two-fold at day 10 compared to other age groups (Figure 4-4).
The other age groups seemed to express similar levels of FcRn proteins.
The two-fold increase of relative FcRn protein expression in 10-day old mice was
also observed in mouse lung compared to 2- and 70- day old groups (Figure 4-6). Thus,
for mouse lung, relative expression was similar in newborn and in adult animals but was
approximately two-fold higher in 10-day old animals.
In mouse kidney, similar levels of relative FcRn protein expression was observed
between 10- and 42-day old age groups. However, these two groups showed a two-fold
increase in relative FcRn protein expression compared to other age groups (Figure 4-5).
The difference in the relative FcRn protein expression was also compared
between males and females within each age group. The results of this analysis, however,
showed that there was no significant sex difference in relative FcRn protein expression in
any age group or tissue (Figure 4-8).
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Figure 4-3. Ontogeny of FcRn protein expression in mouse skin
No significant difference in the relative FcRn protein expression was observed in the skin
of 2-, 10-, 21-, 42-, and 70-day old mice.
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Figure 4-4. Ontogeny of FcRn protein expression in mouse liver
Relative expression of FcRn protein in mouse liver was significantly increased in 10-day
old mice compared to other age groups. The p-values are reported above the lines
associated with each paired comparison.
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Figure 4-5. Ontogeny of FcRn protein expression in mouse kidney
Relative expression of FcRn protein in mouse kidney was significantly increased in 10and 42-day old mice compared to other age groups. The p-values are reported above the
lines associated with each paired comparison.
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Figure 4-6. Ontogeny of FcRn protein expression in mouse lung
Relative expression of FcRn protein in mouse lung was significantly increased in 10-day
old mice compared to 2- and 70-day old animals. The p-values are reported above the
lines associated with each paired comparison.
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Figure 4-7. Ontogeny of FcRn protein expression in mouse spleen
There was no significant difference in the relative expression of FcRn protein in mouse
spleen across age groups.
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Figure 4-8. Sex-specific relative FcRn protein expression during postnatal
development in mouse skin, liver, kidney, lung, and spleen
There was no significant difference in FcRn protein expression between males and
females during development in mouse skin (A), liver (B), kidney (C), lung (D), and
spleen (E).
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Unfortunately, the difference in the relative quantitation of FcRn expression
across various mouse tissues within each age group could not be determined due to the
preliminary results that showed the different levels of GAPDH protein expression across
the tissue observed in a 70-day old mouse (Figure B-6).
Discussion
Western blotting successfully determined the protein expression of FcRn relative
to GAPDH in all organs and tissue samples. Under the reducing conditions of
electrophoresis, double bands and broad bands of FcRn protein were observed at the
molecular weight a 45 ± 55 kDa in mouse liver samples. FcRn protein also produced
broad bands in this molecular weight range in mouse kidney samples. This observation
was not surprising, however, as detection of FcRn protein expression as double bands or
broad bands hasbeen observed in other studies in rat small intestine and hepatocytes [6163, 75, 76]. The broad band of FcRn protein expression was also detected in human
glomerular extract [71]. The double bands and broad bands at 45 ± 55 kDa may indicate
various degrees of posttranslational modification of the FcRn receptor, such as
glycosylation [62, 72, 75]. N-linked oligosaccharides were also shown to significantly
contribute to the heterogeneity in molecular size of the IgE receptor that resulted in
diffuse bands in the 45 ± 62 kDa region [90]. In addition, dimerization of FcRn seemed to
exist, as FcRn proteins from mouse liver could be detected at the molecular weight a 140
± 150 kDa. FcRn protein dimers were also observed in another study, but the molecular
weight was described as 110 kDa [75].
According to the Western blot results, FcRn may be presented in various
glycosylated species in some mouse organs such as liver and kidney. Moreover, the
dimerization of FcRn may be more frequent in mouse liver since the bands related to
FcRn dimers (a 140 ± 150 kDa) were very apparent even under the reducing condition of
electrophoresis. Interestingly, the degree of dimerization seemed to show an ontogenic
pattern with the lowest (a 10%) observed in 10-day-old mice (p < 0.005 compared to 21and 70-day old groups; Table B-1). The maximal level of FcRn dimers was reached at
21-day-old (a 30%) and was constantly expressed later on in 42- and 70-day-old mice.
Comparison of age-dependent expression of FcRn in mouse liver between FcRn
monomers and total FcRn proteins (a mixture of monomers and dimers) across all age
groups showed a similar pattern. However, a less-pronounced effect of ontogeny was
observed when total FcRn protein expression was taken into account, resulting in a
significant difference in total FcRn expression only between day 2 and day 10 age groups
(p < 0.005; Figure B-7).
The current analysis assumed that FcRn was uniformly distributed throughout the
organs and tissues. However, uneven FcRn mRNA and protein expressions have been
reported in rat small intestine, with maximal expression in the proximal duodenum region
and a gradual decline toward the distal small intestine [66, 74-76, 79, 91, 92]. This
differential distribution of FcRn along the intestine may contribute to the negligible
amount of immunoglobulin absorption in the distal small intestine [61, 79, 91-94]. A
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differential distribution of FcRn also appears in the kidney, as high expression of FcRn
was observed with a proximal to the distal gradient in the renal tubular system [66].
Moreover, the white pulp of the spleen was devoid of FcRn expression, whereas strong
expression was detected in the sinusoids of splenic red pulp [66]. The regional variability
of FcRn expression in organs may due to the differential distribution of endothelial cells
in the organs and may be one of the factors that contributed to the variability of relative
FcRn expression on the Western blots. If possible, these factors should be taken into
account in the future studies.
The ontogeny of FcRn expression was investigated with C57BL/6J mice as a
surrogate animal for the ontogeny of human FcRn. Animals of 2-, 10-, 21-, 42-, and 70day postnatal age were selected as representative age groups for neonates, infants,
children, adolescents, and adults. Our results showed a two-fold increase in relative
expression of FcRn in liver and lung of 10-day old mice compared to neonates and adults.
Similarly, relative expression of FcRn was doubled in the kidneys of 10- and 42-day-old
mice. However, the ontogeny of FcRn expression did not seem to exist in mouse skin and
spleen. These results suggested an organ-specific developmental expression of FcRn.
These organ-specific developmental patterns of expression of FcRn are consistent with
the observation of the different patterns of developmental FcRn expression in intestine
and brain capillaries [74-76, 81]. Downregulation of FcRn expression during
development is observed in mouse intestine [74-76], whereas upregulation occurs during
aging in brain capillaries [81].
Relative FcRn expression in liver and lungs showed ontogenic development with
low expression at birth, peak expression at 10 days, and diminishing expression to adult
levels around weaning age (21 days). This developmental FcRn expression exhibits a
similar pattern as in rat intestine [74-76]. The maximal level of duodenal FcRn mRNA
expression exists between 1 and 19 days of age, but is undetectable during fetal life, at
birth, and after weaning [74]. FcRn protein expression is also shown to disappear from
the proximal small intestine of 23-day-old rats (weaning age) [75]. Thus, concordance
between transcription and translation (i.e. mRNA vs. protein expression) seems to exist
for this salvage receptor.
FcRn seems to have distinctive expression patterns in different species. Unlike in
rodents, FcRn is also expressed in human fetal stomach and colon [78]. Moreover, the
differential FcRn expression along the intestine in rodents does not seem to exist in
humans [78]. In contrast, another study reported an increasing proximal-distal gradient of
mucosal FcRn mRNA and protein expression in the adult human intestine, which
translated to higher serum mAb levels after ileum-proximal colon infusion than after
administration to the stomach or proximal small intestine [79]. The difference between
these studies may be due to the ontogenic effect on the differential FcRn expression
pattern along the intestine with the insignificant differential distribution of FcRn in the
human fetus, but an increasing proximal-distal gradient observed in the adult human
intestinal mucosa. The age-dependent expression of FcRn in human intestine and colon
seems to show the reverse direction compared to rodents. Upregulation of FcRn
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expression is observed in the small intestine as well as the colon in older child and
adolescents compared to younger children [78].
The variability in the FcRn expression pattern in various mouse organs during
development might indicate a complex regulatory system that controls the expression of
this receptor. A possible factor that regulates developmental expression of FcRn may be
Fcgrt transcription [95]. The selective temporal and spatial availability of specific
transcription factors within the Fcgrt proximal promoter region may contribute to the
developmental and tissue-specific regulation of Fcgrt expression, which can be observed
as different age-dependent expression patterns of FcRn in different mouse organs.
Although exogenous corticosteroids and thyroid hormone can downregulate FcRn
expression, the endogenous forms of adrenal corticosteroids are assumed to not play a
significant role in regulating the programmed pattern of FcRn expression [96].
Unfortunately, the level of FcRn protein expression could not be compared across
various tissues within each age group of C57BL/6J mice. This was due to the observed
inconsistent expression level of GAPDH that was used as a reference protein in various
tissues. GAPDH has been reported as an inappropriate housekeeping gene for relative
quantitation using RT-PCR or northern blot in, due to variation in expression in various
mouse tissues [97]. However, different levels of endothelial cells expressed across
various organs may result in the variation of FcRn expression in various mouse tissues.
A correlation between the ontogenic pattern of FcRn mRNA expression and IgG
absorption has been described [74]. Postnatal absorption of IgG via FcRn is limited to the
suckling phase in rodents and abruptly decreases at weaning [74, 94]. This alteration
coincides with a significant induction of FcRn mRNA expression during the first day of
life and a substantial decline in expression at the age of weaning [74]. Thus, the
developmental alterations in the relative expression of FcRn may have an impact on the
pharmacokinetics of therapeutic proteins that bind to this receptor. A prolonged half-life
might be observed during the ages of high expression if liver, lung, and/or kidneys are the
major organs of drug disposition. However, the endothelial cells in skin, muscle, and
liver, along with the hematopoietic cells, have been shown to be the primary sites of
functional FcRn expression in adult mice. This may indicate that these organs are the
major sites of serum IgG homeostasis [68]. The primary sites of FcRn that are
responsible for maintaining the IgG levels in adult mice have been shown to be
endothelial cells and hematopoietic cells [89]. Moreover, based on physiologically based
pharmacokinetic modeling, the contribution of various organs to the elimination of
endogenous IgG was estimated to be 33%, 24%, 16%, and 12% for skin, muscle, liver
and gut tissue, respectively [4]. Consequently, the ontogenic patterns of FcRn expression
observed in mouse liver, kidney, and lung might not have a significant impact on the
pharmacokinetics of therapeutic proteins that can bind to this salvage receptor. To further
elucidate this question, a pharmacokinetic study using a therapeutic protein with its
disposition largely affected by FcRn in different age groups of mice is needed. This
pharmacokinetic study was performed and the results are reported and discussed in the
next chapter.
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CHAPTER 5. PHARMACOKINETICS OF A HUMAN MONOCLONAL
ANTIBODY DURING THE POSTNATAL DEVELOPMENT PROCESS IN MICE
Introduction
In recent years, there is an increasing number of antibody-based therapeutic
proteins have been approved for pediatric use, spanning from intact mAbs to IgG Fcfusion proteins. However, the application of therapeutic proteins in pediatrics has often
been based on the extrapolation of clinical findings from adults. This is frequently due to
the lack of evidence of the efficacy and safety in pediatric populations, the difficulties in
conducting pediatric clinical trials, a lack of financial incentives, and no mandatory
regulatory requirements for pediatric development in the past [8, 26]. Although
extrapolation may be useful when lacking pediatric data, this approach may significantly
compromise the prediction of efficacy and safety in pediatric patients if the dissimilarities
between children and adults are not well understood. Thus, the rational application of
therapeutic mAbs in children requires a fundamental understanding of the similarities and
differences in disease pathophysiology, pharmacokinetics, and pharmacodynamics
(PK/PD) between children and adults, and informative clinical trials to define the optimal
dosage regimens for children and evidence-based pediatric treatment guidelines.
As a first step toward achieving a better understanding of the pharmacokinetics of
therapeutic mAbs in growth and maturation, the pharmacokinetics of AMG589, a fullyhuman mAb, was studied in various age groups of C57BL/6J mice. AMG589 was in this
context solely used as a model compound for a mAb and does not bind to a specific target
in mice. The effect of several factors, including weight and age, were explored and
evaluated in this study to determine their impact on the pharmacokinetics of mAbs during
postnatal development in mice. Due to the rapid growth of mice during the early phase of
their development relative to the long half-life of mAbs, body size measures such as
weight are expected to be the major factor that affects the pharmacokinetics of AMG589.
Because of the significant influence of FcRn on the half-life of mAbs, the effect of
developmental changes in FcRn expression level in various organs on the
pharmacokinetics of AMG589 is one potential covariate affecting mAb disposition and
was investigated across all age groups of mice. Other factors that needed to be considered
are the promiscuity in the binding of mouse FcRn to human IgG and potential
immunogenic events, such as the formation of anti-drug antibodies that might occur
during the study.
The results of the relative quantification of FcRn expression in various organs of
2, 10, 21, 42, and 70 day old C57BL/6J mice as described in Chapter 4 showed no
difference in the relative FcRn protein expression across age groups in skin and spleen.
However, the relative FcRn protein expression exhibited organ-specific ontogenic
patterns in liver, lung, and kidney. Two-fold increases in FcRn expression were observed
in liver and lung of 10-day old mice, whereas FcRn expression in kidney showed twofold increases in 10 and 42 day old mice. This organ-specific pattern in the ontogeny of
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FcRn expression may have an effect on the pharmacokinetics of AMG589 in the
contribution of the organ to the overall clearance of mAbs.
The skin has been shown to contribute most to the homeostasis and the
elimination of IgG [68]. Recent reports suggest FcRn may play a role in subcutaneous
absorption and degradation of mAbs [55]. Although the presence of FcRn in
subcutaneous tissue has not been reported beyond endothelial and some immune cells,
FcRn expression has been detected in the epidermis, dermis, and skeletal muscle.
Because quantitation of FcRn expression in skin in Chapter 4 did not reveal any
ontogenic pattern, the pharmacokinetics of AMG589 should not be affected by FcRn
expression in the skin across age groups.
FcRn expression in bronchial and/or alveolar epithelial cells has been shown to
enhance the pulmonary absorption of IgG and Fc-fusion proteins [55]. However,
AMG589 was administered via a subcutaneous route in this study. Thus, intuitively, the
increased expression of FcRn in the lungs of 10 days old C57BL/6J mice should not have
any influence on the pharmacokinetics of AMG589 in this study if the lungs are not a
major elimination organ for IgG.
FcRn has been shown to facilitate transport of IgG across both the glomerular and
proximal tubule membranes. This provides an efficient recycling mechanism that
prevents accumulation of IgG along the podocyte slit diaphragms [55]. However, the
renal impairment has minor or no effect on the systemic clearance of therapeutic mAbs
[55, 98]. Thus increasing FcRn expression in the kidneys of 10- and 42-day-old mice may
not render any effect on the pharmacokinetics of AMG589.
Based on the current evidence in the literature and the results of the ontogeny of
FcRn expression in Chapter 4, we hypothesized that the pharmacokinetics of AMG589
in different age groups of C57BL/6J mice would not be affected by the organ-specific
ontogenic patterns of FcRn expression observed in mouse liver, lung, and kidney after
accounting for the alteration in body size during postnatal development. To test this
hypothesis, a population pharmacokinetic analysis approach was used to delineate the
factors that influence the pharmacokinetics of AMG589 during the development of
C57BL/6J mice.

Method
Animals
Nine timed-pregnant C57BL/6J mice were purchased from The Jackson
Laboratory (Bar Harbor, ME) and were shipped to arrive on day 13 of gestation. All
timed-pregnant mice were housed with free access to food and water in the animal
facility at the University of Tennessee Health Science Center for 1 week. The day of birth
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of the offspring was assigned as their first day of life (day 1). The offsprings were raised
to pre-determined postnatal ages including 2, 10, and 21 days. All pups were weaned at
21 days. Male and female pups were separately housed in different cages at weaning.
Due to one mouse not being pregnant, only ten 21 day old mice were available.
However, at least 18 mice in each age group were needed for the pharmacokinetic study
in order to get at least three mice at each blood sampling point. As a result, eight
additional 21 day old C57BL/6J mice (4 males and 4 females) were purchased from The
Jackson Laboratory (Bar Harbor, ME). For the 42 and 70 day old groups, nine male and
nine female C57BL/6J mice of each age group were also purchased from The Jackson
Laboratory (Bar Harbor, ME). All animals were housed in standard laboratory cages
throughout the study. The study was conducted according to the guidelines of the Animal
Welfare Act and the Public Health Service Policy on Humane Care and Use of
Laboratory Animals, and the protocol was approved by the Institutional Animal Care and
Use Committee of the University of Tennessee Health Science Center. The number of
animals in each age group and their demographic characteristics are shown in Table 5-1.
Pharmacokinetic Study
AMG 589, a fully-human monoclonal antibody, was kindly provided by Amgen
Inc. (Thousand Oaks, CA) and was used as a model drug for studying the
pharmacokinetics in different age groups of mice. AMG 589 was subcutaneously
administered at 39 mg/kg in 2 day old mice and at 50 mg/kg in 10, 21, 42, and 70 day old
C57BL/6J mice. Blood was collected by cardiac puncture from 3 or 4 mice in each age
group at 2, 24, 72, 168, 336, and 504 hours post-dose, except 42 day old mice, in which 3
mice were sacrificed at 2, 24, 96, 168, 336, and 504 hours post-dose. All dosing and
blood sampling schemes are shown in Table 5-2. Blood was kept in BD Vacutainer® Plus
plastic serum tubes with additive clot activator and gel for serum separation (Franklin
Lakes, NJ). Serum was separated by centrifugation for 16 minutes at 2500 × g at 4qC. All
mouse serum samples were subsequently stored at -70qC before shipping to Amgen Inc.
(Thousand Oaks, CA) for further analysis.
Quantification of AMG589 in Mouse Serum Samples
Courtesy of Amgen Inc (Thousand Oaks, CA), all mouse serum samples from the
pharmacokinetic study were quantified for AMG589 using ELISA according to the
company protocol. The variability of the assay was about 15%. The calibration range of
the assay was 10 ± 10,000 ng/mL, and LLOQ was 10 ng/mL. Due to the limited volume
of serum acquired from one animal of the 2-day group at the 2-hour sampling time, only
two samples were quantified at this time point.
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Table 5-1.
Demographic characteristics of C57BL/6J mice included in the
pharmacokinetic study of AMG 589
Characteristics
Day 2a
Day 10
Male
Female
Day 21
Male
Female
Day 42
Male
Female
Day 70
Male
Female
a

Average weight (g) (Range)
0.9 (0.9 ± 0.9)

Number of animals
20

3.6 (2.9 ± 4.3)
3.6 (3.0 ± 4.9)

8
11

10.7 (2.5 ± 16.1)
9.6 (6.4 ± 14.0)

8
10

15.6 (13.0 ± 19.0)
12.7 (11.0 ± 15.0)

9
9

19.4 (16.3 ± 23.5)
15.1 (11.0 ± 18.0)

9
9

Based on mouse anatomy, sex determination was not possible in the day 2 age group.

Table 5-2.
Dosing and blood collection scheme for the pharmacokinetic study of
AMG589 in different age groups of C57BL/6J mice
Age at
dosing
(days)
2

Dose
(mg/kg)
39

Total
number
of mice
20

10

50

19

21

50

18

42a

50

18

70

50

18

Number of mice at each sampling time point
2h
24 h
72 h/
168 h 336 h 650 h
96 h
3
1M
2M
1M
2M
3M
2F
1F
2F
2F
1F
1M
1M
1M
2M
1M
2M
2F
2F
2F
1F
2F
2F
2M
1M
1M
2M
1M
1M
1F
2F
2F
1F
2F
2F
a
1M
2M
1M
2M
1M
2M
2F
1F
2 Fa
1F
2F
1F
2M
1M
2M
1M
2M
1M
1F
2F
1F
2F
1F
2F

Note: M and F represent male and female, respectively.
a
42 day old mice were sacrificed at 96 hours instead of 72 hours after dosing.
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Pharmacokinetic Data Analysis
The full dataset contained one observation from each mouse at each sampling
time point. Due to insufficient serum obtained from one mouse in the day 2 age group, 92
observations were obtained in total. The sex of the mice in the 2 days old age group could
not be identified at the 2-hour sampling time point. In this case, all animals in this group
and time point were assigned to be male in the dataset. Weights of male and female mice
in each age group at the time of dosing were imputed for each data record before data
analysis.
In an exploratory data analysis that plotted the serum concentration-time profiles
of AMG589 in different age groups of C57BL/6J mice, high variation at 24 hours in 42
day old mice (RSD ~87%) may have been caused by experimental error. Thus, two
datasets were created²one with and one without these questionable data points. The
dataset that excluded serum concentrations of AMG589 at the 24-hour time point was
first analyzed and used for population model building. The full dataset that included the
serum concentrations of AMG589 at the 24-hour sampling time was then subsequently
analyzed with the same modeling approach as that used for the first data set.
Non-Compartmental Analysis
A non-compartmental pharmacokinetic analysis of the concentration-time data
was performed using PhoenixTM WinNonlin® version 6.3. By this approach, the
pharmacokinetic profiles of AMG589 were separately analyzed according to age group
with uniform weighing in the two datasets--the one excluding serum concentration-time
profile of AMG589 at the 24-hour time point and the full dataset.
Population Pharmacokinetic Analysis
To explore covariates that may affect the pharmacokinetics of AMG589 in
different age groups of C57BL/6J mice, a population pharmacokinetic approach using
nonlinear mixed effects modeling was applied using NONMEM software version 7.2
(ICON Development Solutions, Hanover, MD) with the Pirana version 2.9.0 platform
(®Pirana Software & Consulting BV, http://www.pirana-software.com). R (The R
Foundation for Statistical Computing) with Xpose and ggplot2 packages was used within
Pirana version 2.9.0 for graphical visualization of the results [99]. The effects of body
weight, age, and FcRn expression on the pharmacokinetics of AMG589 in different age
groups of C57BL/6J mice were explored. The population pharmacokinetic model was
developed using the dataset that excluded serum concentration-time data of AMG589 in
C7BL/6J mice at the 24-hour time point. The final model was then applied to the full
dataset.
Based on the serum concentration-time profiles of AMG589 in different age
groups of C57BL/6J mice that exhibited a single phase of distribution and elimination,
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along with the information that subcutaneous injection was the route of administration for
AMG589, a one-compartment linear model with first-order absorption was chosen to
build the structural model. The FOCE method within NONMEM was used throughout
the model-building process.
Between-subject variability (K) for AMG589 pharmacokinetic parameters was
assumed to follow a log-normal distribution with zero mean and variance Z2. Thus, an
exponential error model was applied for the estimation of K (Equation 5-1). A
proportional error model was applied for the estimation of the residual error (Hij) that was
assumed to be normally distributed with zero mean and variance V2 (Equation 5-2). The
choice of the proportional residual error model is supported by the fact that all measured
serum concentrations were far larger than the lower limit of quantification of the assay.
ܲ ൌ ܲ ൈ  ݁ K
ܥǡ௦௩ௗ ൌ ܥǡௗ௧ௗ  ൈ ሺͳ   ߝ ሻ

(Eq. 5-1)
(Eq. 5-2)

The covariate effect was then explored and subsequently added to the structural
model. Pharmacokinetic parameters such as clearance (CL) and volume of distribution
(V) are usually functions of body size; thus the effect of body size can overlay and may
potentially mask the effect of other covariates. To identify covariates other than body
size, these pharmacokinetic parameters should first be adjusted to an appropriate body
size measure [100]. According to this consideration, body weight was the first covariate
incorporated into the structural model by the widely used allometric scaling approach [8,
100]. After accounting for the body size effect, other covariates such as age and FcRn
expression were subsequently evaluated.
Rapid growth during the first phase of development in the C57BL/6J mice
resulted in great relative changes in body weight throughout the sampling period, which
potentially had an impact on the pharmacokinetics of AMG589 during the study period.
As a result, mouse body weight was incorporated in the structural model with
consideration of the incremental changes in mouse body weight during development. The
first step was to explore the growth pattern of C57BL/6J mice by plotting the mean body
weights of male and female mice against age at the time of dosing from each studied age
group (Figure 5-1) and comparing them with the reported growth curves for C57BL/6J
mice. The mean body weights of male and female mice at various time points were then
derived from Equation 5-3.
ܹܤ ൌ ͲǤͻ 

ܹ௫  ൈ ሺ݁݃ܣሻே
݁݃ܣହ ே   ሺ݁݃ܣሻே
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(Eq. 5-3)
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Figure 5-1. Growth curves of male and female C57BL/6J mice
Comparison of the actual growth curves of male and female C57BL/6J mice in the study
and the growth curves of male and female C57BL/6J mice obtained from information at
Jackson Laboratories
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BWP is the predicted body weight (g) of male or female C57BL/6J mice at
various time points during the study period, 0.9 is the mean body weight (g) of 2 day old
C57BL/6J mice in the study, Wmax is the maximal body weight (g) of the male or female
C57BL/6J mice presented in the growth curve, Age is the age of mice (days) at individual
time points, N is the sex-specific hill coefficient that describes the growth curve of male
or female C57BL/6J mice in the study, and Age50 is the age of male or female mice
(days) at which they reach 50% of maximal body weight.
Age (days), which represents the age of C57BL/6J mice at individual time points,
can be estimated from the age at dosing or AAD (days) and time after dosing, TAD
(days), as shown in Equation 5-4.
Age = (AAD) + TAD
(Eq. 5-4)
When comparing the growth curves of C57BL/6J mice in this study to those of
the same mouse species from the Jackson Laboratories, there was some deviation (Figure
5-1). To account for this deviation, nominal body weights of male and female mice at the
time of dosing were first determined from the growth curve by Equation 5-5 (similar to
Equation 5-3).
ܹܤ ൌ ͲǤͻ 

ܹ௫  ൈ ܦܣܣே
݁݃ܣହ ே   ܦܣܣே

(Eq. 5-5)

By replacing the age of mice (days) at individual time points with the age of mice
at the time of dosing (days), nominal body weights (g) of male and female C57BL/6J
mice at the age of dosing can be determined from the growth curve. A multiplier, or
correction factor (F), to account for the differences between nominal and actual body
weights, was defined by dividing the actual body weight (Wt) of male and female mice at
the time of dosing with the corresponding nominal body weight at the age of dosing,
BWAAD (Equation 5-6). The sex-specific multiplier (F) was then used to adjust the
predicted body weights of male and female mice (BW) for their actual body weight at the
time of dosing (Equation 5-7).
 ܨൌ

ܹݐ
ܹܤ

 ܹܤൌ  ܨൈ  ܹܤ 

(Eq. 5-6)
(Eq. 5-7)

The body weight (BW) was subsequently incorporated into the structural model
by the allometric scaling approach using Equation 5-8.
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 ܹܤ
ܲ ൌ  ߠ ൈ  ൬
൰
ܹܤௗ

(Eq. 5-8)

P is the pharmacokinetic parameter that represents clearance (CL), or volume of
distribution (V). ߠ is the typical value of each pharmacokinetic parameter. BW is the
predicted mouse body weight at various time points, and BW70d is the average body
weight in g of a 70 day old male C57BL/6J mouse. b is the allometric exponent that
describes the relationship between the pharmacokinetic parameter and body weight.
Due to the limited and sparse data in this study, the exponent (b) of the power
function in allometric scaling may be inaccurately estimated [8]. Moreover, fixing the
allometric exponent helps in delineating the size effect from other covariates which may
show a high degree of collinearity with body size [8, 100]. Thus, the allometric exponent
was fixed to 1 for the volume of distribution (V). Because of disagreement in the
scientific literature over the appropriate exponent on CL for mAbs, the exponent on CL
was tested and selected between two options, 0.75 and 0.85, before fixing [101].
After the effect of mouse body weight was accounted for and incorporated into
the structural model, the effects of age and FcRn expression from various organs were
subsequently explored. Different patterns of covariate effects were investigated
(Equations 5-9 to 5-13).
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൰൨
ܹܤௗ
ܸܱܥெ
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(Eq. 5-9)

(Ep. 5-10)

(Ep. 5-11)

(Eq. 5-12)

(Eq. 5-13)

P, TP, b, BW, and BW70d represent the parameters that were already described.
COV represents the covariate of interest including age and relative FcRn expression in
various organs in different age groups of C57BL/6J mice. COV70M is the mean value of
the covariate of interest in 70 day old male C57BL/6J mice. TC is the parameter to be
estimated that best describes the relationship between the pharmacokinetic parameter and
the covariate.
Relative FcRn protein expression in various organs during postnatal development
of C57BL/6J mice was obtained from the study described in Chapter 4. Mean FcRn
expression results from the sample set with 20 g protein loading were used for the
investigation of covariate effects. (Table 5-3). Mean FcRn expression of mice in each
age group was normalized to mean FcRn expression of 70 day old C57BL/6J mice in the
model.
The covariate model was built using a stepwise forward addition/backward
deletion modeling approach [102]. The criterion for inclusion of a covariate in the model
was a decrease in objective function value (OFV) of 3.84 (p < 0.05). Due to the multiple
comparisons inherent in the forward addition procedure, more stringent criteria with a
change in OFV of 10.8 (p < 0.001) was required for a covariate to remain in the model
during the backward deletion step [103]. Moreover, goodness-of-fit plots and changes in
between-subject variability, along with the standard error of the parameter estimates,
were considered criteria for model selection. The final model was subsequently applied to
the full dataset that included the serum concentration-time data of AMG589 at the 24hour time point.
Population Pharmacokinetic Model Evaluation
The precision and stability of the final model estimates were evaluated by
nonparametric bootstrap analysis, and the ability of the final population pharmacokinetic
model to adequately describe the observed data in the full dataset was determined by
visual predictive check. The full dataset was used for model qualification, which was
performed by using PsN (GNU General Public License, version 2) [104] using the Pirana
version 2.9.0 platform (®Pirana Software & Consulting BV, http://www.piranasoftware.com). Graphical visualization of the results was performed using the ggplot2
package in R (The R Foundation for Statistical Computing) via the Pirana version 2.9.0
platform.
Bootstrap Analysis
500 bootstrap datasets were created by repeatedly random sampling with
replacement from the original full dataset. Each bootstrap dataset contained the same
sample size as the original dataset. With the stratified sampling approach on age at
dosing, the same ratio of samples in each age group as those in the original dataset were
created. The population parameters were subsequently estimated for each bootstrap
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Table 5-3.
mice
Age
(days)
2
10
21
42
70

FcRn expression in various organs during development in C57BL/6J

Skin
0.68
0.57
0.80
0.75
0.46

FcRn expression (20 g loading sample set)
Liver
Kidney
Lung
0.66
0.63
0.75
1.45
2.29
1.93
0.81
1.15
1.10
0.81
2.29
1.12
0.71
0.94
0.70

70

Spleen
1.17
0.96
0.39
0.59
0.43

dataset using the final population pharmacokinetic model. Based on 500 estimations, the
median and 90% confidence intervals (CIs) for each parameter were derived and
compared to the final estimates obtained from the original dataset.
Visual Predictive Check
1000 simulations were performed using the final population pharmacokinetic
model with the final parameter estimates and their distributions. To preserve the data
distribution in each age group of the original dataset, the simulations were stratified on
age at dosing of mice. The median and 90% CIs of AMG589 plasma concentration at
each time point were subsequently determined from the simulated plasma concentrations
data. The median and 90% CIs obtained from simulated plasma concentrations data were
plotted and overlaid with the observed concentrations.
Results
Serum concentration-time profiles of AMG589 following subcutaneous (SC)
administration at 39 mg/kg in 2-day old mice, and at 50 mg/kg in 10, 21, 42, and 70 day
old mice were similar across all age groups (Figure 5-2). A single phase of distribution
and elimination was observed in the serum concentration-time profiles of AMG589 in all
age groups of mice. Lower serum concentrations of AMG589 were observed in the 2 day
old C57BL/6J mice. Scaling the SC dose administered in 2-day old mice from 39 mg/kg
to 50 mg/kg (Day 2 (50 mg/mL) in Figure 5-2) showed a slight increase in AMG589
systemic exposure, but did not significantly change the non-compartmental
pharmacokinetic analysis results (Table 5-4). Compared to other age groups, a slightly
flatter terminal disposition phase was observed in the serum concentration-time profile of
42 day old C57BL/6J mice. The pharmacokinetic parameters obtained by standard noncompartmental analysis are listed in Table 5-4.
The results of the non-compartmental analysis revealed smaller values for
apparent clearance (CL/F) and apparent volume of distribution (V/F) in the full dataset
compared to those in the dataset that excluded serum concentration-time data of
AMG589 at the 24-hour time point. However, both data sets showed the same pattern of
changes in CL/F across all age groups of C57BL/6J mice. Decreasing CL/F was observed
as mice aged, until the age of 42 days. 70 day old C57BL/6J mice showed increased CL/F
of AMG589 compared to 42 day old mice. The value of CL/F in 70 day old mice was the
same as that in 21-day old mice. V/F of AMG589 in both datasets also exhibited a similar
pattern of change across all age groups of C57BL/6J mice. Decreased V/F of AMG589
was observed during the developmentof C57BL/6J mice until the age of 42 days. In the
full dataset, V/F of AMG589 in 42 day old mice was of the same magnitude as that in 70
day old mice, whereas increased V/F was observed in 70 day old C57BL/6J mice in the
dataset that excluded AMG589 serum concentration-time data at 24 hours.
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Figure 5-2. Serum concentration-time profiles of AMG 589 in different age
groups of C57BL/6J mice (n = 3- 4) in the full dataset

Table 5-4.
Non-compartmental pharmacokinetic parameters of AMG589
following SC administration in different age groups of C57BL/6J mice
Parameters
Exclusion of
24-hour data
CL/F
V/F
Oz
t1/2
Full dataset
CL/F
V/F
Oz
t1/2

Day 2a

Day 2b

Age
Day 10 Day 21

Day 42

Day 70

mL/day/kg
mL/kg
1/day
day

58.4
550.
0.106
7

60.0
565
0.106
7

24.8
271
0.0913
8

9.85
159
0.0619
11

6.34
126
0.0501
14

11.0
140.
0.0781
9

mL/day/kg
mL/kg
1/day
day

53.7
506
0.106
7

54.1
510.
0.106
7

22.3
245
0.0913
8

9.26
150.
0.0619
11

6.22
124
0.0501
14

9.97
128
0.0781
9

Units

a

Instead of the 50 mg/kg SC dosing of AMG589, 39 mg/kg was SC administered in 2
day old mice.
b
The pharmacokinetic parameters were derived from the plasma concentrations that were
scaled to those after SC dosing at 50 mg/kg.
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The elimination rate constants (Oz) and half-lives (t1/2) of AMG589 in C57BL/6J
mice were the same between the two datasets. Oz dropped from the first day of life until
the age of 42 days and rose again in 70-day old mice. As a consequence, t1/2 of AMG589
increased until the age of 42 days and then dropped in 70 day old C57BL/6J mice.
A one-compartment model with first-order absorption was applied to the
structural model in the population pharmacokinetic modeling. Inclusion of body weight
(BW) by the allometric scaling approach with fixed allometric exponent (b) (Equation
5-8) on CL (b = 0.75) and V (b = 1) resolved the problem that was encountered in the
structural model regarding the estimates were near the boundary, decreased the objective
function value (OFV) by approximately 50.8, and improved the goodness-of-fit plots.
Comparison of the allometric exponent (b) on CL between 0.75 and 0.85 showed
comparable results in the OFV and values of parameter estimates (Table 5-5). However,
a b value of 0.75 yielded less %RSE of the parameter estimates compared to the b value
of 0.85. Fixing the exponent at 0.75 seems to follow an underlying physiological
principle [8, 100] and has been successfully used in the population pharmacokinetics of
ciprofloxacin in pediatric patients [103]. Thus b was fixed at 0.75 for CL and at 1 for V
before the next step in the modeling process.
The effects of the remaining covariates were subsequently explored. The plots of
the between-subject variability (ETA) of each pharmacokinetic parameter (CL, V, and
Ka) versus each covariate (sex, age, and FcRn expression in each organ) suggested a
potential effect of age and FcRn expression on CL and V (Figures C-1 to C-4). Betweensubject variability of Ka seemed not to be explainable by any of these covariates (Figures
C-5 to C-6). Additional age effects on CL and V were first explored with the stepwise
forward addition criteria (at p  0.05, the decrease in OFV should be at least 3.84).Age
was included in the model with a power effect on V, and resulted in a decrease in OFV
about 11.7. After accounting for the age effect, the between-subject variability (BSV; Z2)
reduced from 0.198 to 0.175 for CL, and from 0.212 to 0.148 for V. However, the BSV
for Ka slightly increased from 0.573 to 0.610. The parameter estimate for the age effect
on V was -0.331, which indicated that volume of distribution decreased during
development.
The effect of FcRn expression in various organs of different age groups of mice
was then explored. During the screening with the criteria of the stepwise forward addition
approach, relative FcRn expression in skin and kidney were found to have an influence
on CL, whereas FcRn expressions in skin, liver, lung, and spleen were found to have an
effect on V. The effect of FcRn expression in skin on CL was first included in the model
due to the biggest reduction in OFV (-15.116). Accounting for the effect of skin FcRn
expression on CL further reduced the BSV from 0.175 to 0.00608 for CL, from 0.148 to
0.0905 for V, and from 0.61 to 0.469 for Ka. After adding the effect of skin FcRn
expression on CL, FcRn expression in the spleen was the only covariate that had a
significant effect on V (change in OFV was -4.36). However, during the backward
deletion step with stricter criteria (increase in OFV at least 10.8; p  0.001), FcRn
expression in the spleen was excluded in the final model.
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Table 5-5.

Comparison between two values of the allometric exponent (b) on CL

Parameters
CL (mL/day)
TCL
V (mL)
TV
Ka (day-1)
TKa
BSV
Z2CL
Z2V
Z2Ka
Residual error
V2ij

b = 0.75 (OFV = 1708.13)
Parameter
%RSE
estimate

b = 0.85 (OFV = 1709.74)
Parameter
%RSE
estimate

0.135

11.9

0.142

12.3

3.37

15.9

3.44

14.5

2.63

36.7

2.64

40.9

0.198
0.212
0.573

65.2
47.6
87.6

0.221
0.227
0.618

92.3
101
152

0.0260

0.0179
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Due to the very low BSV for CL (0.006) with very high %RSE (1318.3),
removing this parameter from the final model resulted in almost the same final parameter
estimates with significantly reduced %RSE of BSV for V and for proportional error
(decreasing from 179% to 63.5% and 118.8% to 30.5%, respectively) observed in the
model-building dataset (results not shown). When we applied this approach to the full
dataset, almost the same final parameter estimates with comparable %RSE were observed
(results not shown). The final model thus contained only BSV for V and Ka. The
parameter estimates obtained from the final model are shown in Table 5-6 and the
goodness-of-fit plots are shown in Figure 5-3.
The final model was successfully applied to the full dataset that included serum
concentration-time data of AMG589 at the 24-hour time point. The parameter estimates
obtained from the final model in the full dataset are presented in Table 5-6. The
goodness-of-fit plots of the final model applied in the full dataset are depicted in Figure
C-7 in Appendix C. The final parameter estimates obtained from both datasets were
comparable.
The precision of the final parameter estimates obtained from the final model was
subsequently qualified by bootstrap analysis. The medians along with 90% CIs of the
parameter estimates obtained from the nonparametric bootstrap are tabulated in Table
5-6. The median population parameter estimates from the bootstrap analysis were
generally within 3% of the estimates from the final model applied to the full dataset,
except for those of BSV on V and residual error, which showed larger deviations. These
results confirm the stability and robustness of the final population pharmacokinetic
model. The 90% CIs for the covariate effects did not include zero, supporting the
statistical significance of the covariates included in the final model.
The predictive capability of the final model was further evaluated by visual
predictive check plots (Figure 5-4). 1000 simulations with age stratification based on the
final model showed the observations in the full dataset (dots) were reasonably-well
predicted by the median (black line) and mostly captured within the simulated 90%
prediction interval (red lines) in all age groups. Based on these qualification results, the
final population pharmacokinetic model seems suitable to describe the observed
pharmacokinetics of AMG589 in different age groups of C57BL/6J mice.
Discussion
The two objectives of this study were to explore the pharmacokinetics of mAbs in
different age groups of mice and to determine the covariates that potentially have a
significant impact on the pharmacokinetics of therapeutic mAbs during development and
maturation. The effect of FcRn expression is of special interest due to published evidence
that suggests a role for this recycling receptor in the pharmacokinetics of mAbs and the
potential for postpartum ontogeny of FcRn expression. Thus AMG589, a fully-human
mAb, was used as a model drug to study the changes in pharmacokinetics of mAbs in 2,
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Table 5-6.

Parameter estimates obtained from the final population pharmacokinetic model

Model
CL (mL/day)
 ܹܤǤହ
ߠ ൈ  ൬
൰
ͳͻǤͶ
ܴ݊ܿܨ௦ ఏೞೖ̴ಷೃ
ൈ൬
൰
ͲǤͶ
V (mL)
ܹܤ
ߠ ൈ ൬
൰
ͳͻǤͶ
 ݁݃ܣఏಲ
ൈ൬
൰
ʹͶ ൈ Ͳ
Ka (1/day)
ߠ
Covariates
FcRn expression in mouse
skin
Age
Between-subject
variability (BSV)
ܸ ൌ ߠ  ൈ  ݁ Kೇ
K
ܭ  ൌ ߠೌ  ൈ  ݁ ಼ೌ
Residual variability
ܥǡ௦௩ௗ
ൌ ܥǡௗ௧ௗ 
ൈ ሺͳ   H ሻ

Parameters

Model building dataset
Parameter
%RSE
%Shrinkage
estimate

Parameter
estimate

Full dataset
%RSE
%Shrinkage

Bootstrapa
Parameter
90%CI
estimate

TCL

0.191

8.30

0.184

8.40

0.183

0.161-0.219

TV

2.42

10.7

2.17

8.70

2.20

1.91-2.57

TKa

3.08

38.0

3.02

21.6

2.97

2.05-4.53

Tskin_FcRn

-1.36

23.8

-1.17

25.6

-1.18

(-1.87)-(-0.631)

TAge

-0.336

24.2

-0.375

14.4

-0.368

(-0.445)-(-0.278)

Z2V
Z2Ka

0.0816
0.460

63.5
91.1

53
67

0.0341
0.604

120.
64.2

65
65

0.0479
0.608

0.00655-0.127
0.0760-1.95

V2

0.0893

30.5

18

0.101

28.7

13

0.0853

0.0462-0.124

a

Bootstrap analysis was performed on full dataset.
BW is mouse body weight calculated as described by Equations 5-4 to 5-7.
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Figure 5-3.
data set

Goodness-of-fit plots of the final model applied to the model building

Figure 5-4. Visual predictive check for the final population pharmacokinetic
model applied to the full dataset
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10, 21, 42, and 70 day old C57BL/6J mice that were selected as representative age groups
for neonates, infants, children, adolescents, and adults.
The results from the non-compartmental analysis of the pharmacokinetics of
AMG589 in different age groups of C57BL/6J mice revealed comparable values for the
parameter estimates with slightly lower values for apparent clearance (CL/F) and
apparent volume of distribution (V/F) observed in the full dataset when compared to the
dataset that excluded data at the 24-hour sampling time. The results of this analysis,
however, should be interpreted with caution. The methodology for the noncompartmental analysis assumes a constant clearance during the sampling period, but due
to weight and potential maturational changes this is clearly not the case in our analysis. In
addition, some pharmacokinetic parameters are normalized for weight at dosing, but
again, weight changes dramatically over the sampling interval, especially in the younger
animals. Thus, the results of the non-compartmental analysis give a time-averaged
estimate for initial comparisons between the age groups, but the subsequent model-based
analysis provides a more precise assessment of the age-associated changes of AMG589
disposition in mice.
In the full dataset, CL/F and V/F across all age groups were 6.22 ± 53.7
mL/day/kg and 124 ± 506 mL/kg, respectively, whereas 6.34 ± 58.4 mL/day/kg of CL/F
and 126 ± 550 mL/kg of V/F were observed in the dataset that excluded data at the 24hour sampling time. Scaling the original SC dose of 39 mg/kg in two day old mice to 50
mg/kg yielded similar pharmacokinetic parameters. The highest values for CL/F and V/F
were observed in the youngest age group. Both parameters had a tendency to decrease in
value as the animals aged. Although these observations indicate that CL and V of the
younger animals were higher than those of the adults, they could also suggest the
possibility of low bioavailability (F) during the beginning of life. However, a potentially
lower bioavailability occurring in neonates is difficult to mechanistically explain due to
many potential factors, such as the thickness of skin and lymphatic supply at the injection
site, which might have influenced the absorption process [8, 26].
CL/F and V/F of AMG589 in 70 day old mice were comparable to those of
rituximab (CL a 13.8 mL/day/kg and Vss a 156 mL/kg) after IV administration at 40
mg/kg in male C57BL/6J mice (average weight a 18 ± 22 g) [105]. Terminal half-lives
(Oz) were the same in both datasets and ranged from 7 ± 14 days. Half-life was shortest in
the two youngest age groups (2- and 10- days old) and increased slightly in older groups
until the age of 21 days. The half-life of AMG589 in 70 day old mice (9 days) was also
comparable to that observed for rituximab (8 days) [105] and other mouse IgG1s (9 days)
[106] in mice.
Although developmental changes in body composition with decreased total body
water:body fat ratio during maturation have been suggested to not have any significant
impact on the biodistribution of mAbs [8], decreasing volumes of distribution of
AMG589 during development in mice seems to mimic what occurs with the
pharmacokinetics of hydrophilic drugs [107]: a reduction in volume with decreasing
percentage of body water during growth and maturation. However, alterations in the
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biodistribution of AMG589 may also be affected by other changes in body composition
and amount of circulating plasma proteins.
The longest half-life of AMG589 observed in 42 days old C57BL/6J mice
suggests age-dependent pharmacokinetics, which may be the result of several factors. The
drug disposition processes of AMG589 are most likely regulated by common factors and
mechanisms for mAbs, such as their large size, charge, the degree and nature of
glycosylation, and the Fc region [6, 55, 101, 105]. In many cases, mAb elimination is
dominated by affinity for the FcRn receptor and their susceptibility to proteolysis. In
contrast, the ontogeny of small molecular drug transporters in the liver and kidney, along
with the alteration of hepatic drug-metabolizing enzymes during development [25, 107],
should not have any effect on the pharmacokinetics of these macromolecules.
One of the factors that can influence the pharmacokinetics of mAbs is
immunogenicity [4]. In this study, a fully-human mAb, AMG 589, was administered to
mice. This xenogenic antibody can trigger an immune response that may lead to anti-drug
antibody formation, immune complex formation, and ultimately alterations in the
distribution and the elimination rate of AMG 589. This change in distribution and
clearance might have an impact on the efficacy of therapy. However, immunogenicity
seems unlikely in this study since serum concentration-time profiles of AMG589 did not
show any pattern of abrupt decline in the terminal elimination phase, and therapy was
limited to a single dose followed over 3 weeks
The ontogeny of FcRn expression is a major factor of interest since this recycling
receptor contributes to the prolonged half-life of antibody-based therapeutic proteins [70,
88, 106, 108]. The results of our characterization of the ontogeny of FcRn expression in
C57BL/6J mice described in Chapter 4 revealed specific patterns of the ontogeny of
FcRn expression in liver, kidney, and lungs. However, only FcRn expression in the
kidney showed a 2-fold increase at the age of 42 days, which coincides with the
prolonged half-life observed in this age group. The role of renal FcRn in regulating IgG
homeostasis is not clear. Although FcRn has been shown to be involved in the recycling
process of IgG in the kidneys, renal impairment seems to have only minor or no effect on
the elimination of therapeutic mAbs [55, 98]. Thus, the ontogeny of FcRn expression in
the kidneys may not have any impact on the pharmacokinetics of AMG589 in different
age groups of mice.
To explore the covariate effect on the pharmacokinetics of AMG589 in different
age groups of C57BL/6J mice, a population pharmacokinetic modeling approach was
used. A one-compartment linear model with first-order absorption was selected as the
structural model based on the serum concentration-time profile of AMG589 that showed
in a log-linear plot a single terminal disposition phase, which is typical for a non-binding
antibody [109]. Target receptor-mediated metabolism was assumed to be absent in the
elimination of AMG589, a fully-human mAb, since it binds only to its human target
antigen but not the murine homologue. Thus, a simple model such as the onecompartment linear model with first-order absorption rather than a target-mediated drug
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disposition model seems to be a reasonable structural model for describing the
pharmacokinetics of AMG589 in mice.
To account for the effect of body weight on the pharmacokinetics of AMG589, an
allometric scaling approach was applied. One of the assumptions underlying this
technique includes the absence of nonlinear pharmacokinetics, which might not hold true
for most therapeutic antibodies [5]. However, this assumption should be applicable for
the pharmacokinetics of AMG589 due to the lack of clearance through target receptormediated metabolism. Accounting for the body weight effect using the allometric scaling
approach resulted in the reduction in OFV and a better goodness-of-fit plot, which
coincides with reports that reveal body size as the most frequently-identified and
clinically-relevant covariate that influences the pharmacokinetics of antibody-based
therapeutic proteins [8].
Even though several reports have shown that after accounting for the effect of
body size, age has rarely been identified as a covariate that influences the
pharmacokinetics of therapeutic proteins [8], the results in the present study suggested
otherwise. After accounting for the effect of body weight, age was found to affect the
volume of distribution. During development, the volume of distribution of AMG589
seemed to decrease. This finding corresponds to the results obtained from the noncompartmental analysis. As already discussed, this may due to decreasing the percentage
of body water during maturation or it may due to other changes in body composition and
the amount of circulating plasma proteins. Surprisingly, FcRn expression in the skin was
found to be a covariate that affects clearance of AMG589 even though there was no
significant difference in FcRn expression across age groups of C57BL/6J mice (Results
are described and discussed in Chapter 4). With increasing level of FcRn in the skin,
clearance decreased. This result agrees with another study that shows that functional
FcRn receptors are expressed in endothelial cells of the small arterioles and capillaries in
the skin which principally contribute to the homeostasis of IgG [68]. Thus, the
discrepancies between the results of the ontogeny of FcRn expression and population
pharmacokinetic results may disappear when FcRn expression is quantified from the
extracted endothelial cells in skin or the amount of endothelial cells in the skin is taken
into account during data analysis. The population pharmacokinetic results suggested that
the effect of skin FcRn expression and age can cause clearance and volume of
distribution to change by 0 ± 29% and 69 - 279%, respectively.
Although using a fully-human mAb in this pharmacokinetic study may raise
concern regarding the species differences in FcRn binding affinity [5, 6], the half-life of a
fully-human mAb in rodents had been shown to be comparable to that of mouse mAb
versions [55]. However, the 2.5-fold higher binding affinity of human IgG to mouse
FcRn compared to mouse IgG to mouse FcRn [19] may result in masking the potential
effect of FcRn expression in other organs on the pharmacokinetics of AMG589 in
different age groups of mice. To account for species differences in FcRn binding affinity,
a human FcRn transgenic mouse model may potentially be used as a surrogate for
pharmacokinetic studies of humanized or fully-human mAbs [106]. Alternatively, mouse
IgGs could be used as model drugs for the pharmacokinetic study in wild-type mice.
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A sparse dataset with limited observations per individual as analyzed in the
present study has not surprisingly resulted in parameter estimates with relatively high
values of shrinkage for between-subject variability (53 - 67% and 65% shrinkage in
model-building dataset and full dataset, respectively). As a consequence, the final model
derived by the stepwise model-building procedure may suffer from model selection bias,
especially when model selection is based on the graphical evaluation of the goodness-offit plots. However, the final model showed reasonable goodness-of-fit. Moreover, the
final model did not show the perfect fit phenomenon in which the values of individual
predictions shrink towards the actual observations [110, 111] which may result from high
shrinkage (over 20 ± 30%). Although high shrinkage may lead to bias in the model
selection, this selection bias may be of minor importance in the present study because the
purpose of the population modeling was to explore and determine covariates that have
significant influence on the pharmacokinetics of mAbs during the developmental process
in mice, rather than the assessment of between-animal variability.
The findings in this study suggest that body weight along with age are significant
factors that should be considered for dose optimization of therapeutic mAbs in different
age populations. Current practice has also shown that the successful dose extrapolation
from adults to pediatric patients for most therapeutic proteins can be achieved using body
weight or body surface area-adjusted strategies [8, 26]. Using body weight and body
surface area-adjusted dosing strategies, the pharmacokinetics are comparable between
pediatric patients and adults once maturation of drug disposition processes has been
completed. Therefore, the decreasing volume of distribution during maturation may be a
maturation-related factor to consider for the application of therapeutic mAbs in different
age populations. In addition, inter-individual differences in skin FcRn expression
accounted for some of the observed between-subject variability, although no ageassociated changes for skin FcRn expression were observed, at least in mice.
The age groups of mice that were used in this study might not truly represent the
human developmental age; since human newborns are most comparable to 7-day-old
mice in term of immunological development [112]. However, the effect of body weight
on the pharmacokinetics of therapeutic mAbs should be emphasized in pediatrics due to
differential growth rates at young ages that results in a much larger variability in body
size for children than for adults [8, 100]. Moreover, unlike AMG589, many antibodybased therapeutic proteins generally include target receptor-mediated metabolism as a
major elimination pathway. In that case, the prediction of pharmacokinetics in different
age populations becomes more challenging since target antigen levels may be an
additional covariate that influences the pharmacokinetics of the therapeutic mAb. Thus,
differences in target antigen levels between pediatric patients and adults should be
considered during dose optimization in pediatrics for therapeutic proteins that are
eliminated via this saturable disposition process [8].
In conclusion, this study revealed age-dependent pharmacokinetics of AMG589
during the developmental process in mice with the longest exposure observed in 42-day
old animals. The study revealed the effect of body weight, age, and FcRn expression in
the skin as factors that influenced the observed age-dependent pharmacokinetics of
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AMG589 in mice. The importance of body weight adjusted dosing should be emphasized,
especially in pediatrics, since body size rapidly changes during the early period of life.
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CHAPTER 6.

SUMMARY OF DISSERTATION RESEARCH

Advancements in biotechnology have transitioned therapeutic modality from the
use of small chemically-defined molecules to biological macromolecules. Consequently,
a large and increasing number of therapeutic macromolecules are being launched in the
market. Similar to what is necessary with the therapeutic application of small-molecule
therapeutic agents, successful therapy with biotechnologically-derived therapeutic agents
can be achieved by rational therapeutic regimens that are designed based on the
understanding of their pharmacokinetics and pharmacodynamics. However, their
complex structure endows these therapeutic macromolecules with a complicated
disposition pattern that depends on various factors and results in many challenges with
regard to their pharmacokinetic assessment and interpretation. Two challenges that need
to be considered during the interpretation of pharmacokinetic results and the design of
dosage regimens for therapeutic proteins and monoclonal antibodies (mAbs) were
explored in Chapters 3 to 5 of this dissertation: 1) The error of bioavailability
assessment, by using the conventional bioavailability estimation that can be observed
during subcutaneous (SC) administration of therapeutic macromolecules that undergo
target-mediated drug disposition (TMDD) and 2) the ontogeny of FcRn expression along
with its effect on the pharmacokinetics of mAbs during development.
One advantage of therapeutic macromolecules over conventional small-molecule
drugs is their high affinity and specific binding, which result in limited off-target
toxicities. Due to high specificity and affinity of binding to the target receptor, receptormediated metabolism is often the dominant pathway of clearance. This receptor-mediated
metabolism is usually well described by TMDD. However, the limited availability of
target receptors leads to saturation of binding upon dosing, which results in saturation of
the clearance process. The saturation of target receptors under therapeutic concentrations,
along with the high contribution of this process to the overall elimination pathways, can
result in the observed nonlinear pharmacokinetics with decreasing clearance upon
increasing the dose. The nonlinear pharmacokinetics observed for many therapeutic
proteins can have an impact on bioavailability estimation. Bioavailability estimation
based on the classic AUC approach can be erroneous, which is mainly due to the
assumption of dose-independent constant clearance that cannot be applied to therapeutic
proteins that undergo TMDD. To shed light on this issue, we hypothesized that there is a
dose-dependent error in the bioavailability assessment for therapeutic proteins that
undergo TMDD if the classical approach of dose-normalized AUCs is used. The error
becomes apparent when different doses of IV and SC administration are used for
bioavailability estimations, since the clearances at different IV and SC doses are not
equal and change over time, which is dependent on the achieved concentrations.
The results in Chapter 3 support this first hypothesis. Various degrees of error in
the bioavailability estimation were observed after the bioavailability of filgrastim and
denosumab were estimated by a conventional method, using different combinations of
simulated dose-normalized AUCs at various IV and SC doses (0.01 ± 10000 g/kg for
filgrastim and 0.66 ± 210 mg for denosumab). The error became obvious when
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significantly different IV and SC doses were used for the evaluation of bioavailability.
The overestimations were extreme when high SC and low IV doses of both protein drugs
were used for the estimations, whereas the underestimations were exactly the reverse.
The error in the bioavailability estimation originated from different dose-normalized
AUCs observed at various doses.
These variations of dose-normalized AUCs indicated disproportional
characteristic changes in drug plasma concentration-time profiles, which resulted from
changes in clearance upon dose alteration. The transition from low plasma concentration
(at low dose) to high plasma concentration (at high dose) shifted the major elimination
pathway from TMDD to the linear clearance pathways. At low plasma concentration of
the therapeutic protein target receptors have full capacity for elimination; thus TMDD is
the dominant elimination pathway. In contrast, high plasma concentrations at high doses
of protein drugs saturate all target receptors and shift the main elimination pathway to be
governed by linear clearance. The relationship between the simulated plasma
concentrations at different IV doses to the corresponding clearances of both protein drugs
were investigated. The dynamics of the alteration of clearances and dose-normalized
AUCs was parallel and very obvious in the dose range of 0.1 ± 5 g/kg for filgrastim and
below 60 mg for denosumab; thus care should be taken when bioavailability of these two
therapeutic proteins is estimated in these dose ranges. To minimize the error that occurs
when using conventional bioavailability estimation, the bioavailability should be
estimated using dose-normalized AUCs at similar IV and SC doses, or the assessment
should be performed in dose ranges that yield constant dose-normalized AUCs that may
result from concentration-independent clearance (0.01 ± 0.1 g/kg or 5 ± 10000 g/kg for
filgrastim, and 60 ± 210 mg for denosumab). Moreover, an alternative approximation
method could be applied that determines the ratio of IV and SC doses that generate equal
AUCs, as suggested by Gibiansky et al. [51]. Overall, model-based bioavailability
assessment seems to be the most precise approach for therapeutic proteins that undergo
TMDD.
The second challenge related to the ontogeny of FcRn expression and its effect on
the pharmacokinetics of mAbs in different age populations should be of special concern
if therapeutic mAbs are used in pediatric populations. Currently, the dosing regimens for
therapeutic proteins in pediatrics have been generalized from the clinical practice in
adults [8, 26]. Physiological differences in body composition and organ function between
pediatric patients and adults may lead to the age-dependent pharmacokinetics and
pharmacodynamics. The understanding of the developmental changes in the
physiological factors that cause age-dependent pharmacokinetics and pharmacodynamics
are prerequisites for developing effective dosage regimens with maximal efficacy and
low toxicity.
FcRn has been considered a salvage pathway from lysosomal clearance for mAbs
and Fc conjugated proteins [4-7]. This salvage pathway functions through a pHdependent binding process, and can prolong the existence of therapeutic proteins in
systemic circulations. The influence and contribution of the FcRn receptor to the
elimination of mAbs and Fc-conjugated proteins have been shown in many publications
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and have been applied in molecular engineering to generate improved versions of mAbs
and Fc-conjugated proteins with desirable half-lives. The influence of the ontogeny of
FcRn expression on the pharmacokinetics of therapeutic proteins, however, has never
been investigated. The age-dependent expression of FcRn was observed in mouse
intestine with detectable amounts observed up to 3 weeks postpartum [62, 74]. Reduced
expression of FcRn during early developmental stages may result in alterations of the
pharmacokinetics of mAbs upon dosing. Thus, a second hypothesis was established that
the down-regulation of FcRn expression levels during development would result in a
shortened half-life of AMG589 in mice. To test this second hypothesis, three
experimental aims were framed. In the first aim, the levels of FcRn expression in organs
of C57BL/6J mice from postnatal days 2 through 70 were examined. In the second aim,
the pharmacokinetics of AMG589 were studied in different age groups of C57BL/6J
mice. Finally, in the third aim the FcRn expression levels and pharmacokinetics of
AMG589 in the different age groups of mice were correlated using a nonlinear-mixed
effects modeling-based population pharmacokinetic approach.
The findings on the ontogeny of FcRn expression in C57BL/6J mice in Chapter 4
and the results of the pharmacokinetics of AMG589 in various age groups of C57BL/6J
mice in Chapter 5 led to conclusions that negated the second hypothesis. Although FcRn
expression showed an ontogenic pattern, its occurrence was significant in only three
organs: liver, lungs, and kidneys. Moreover, the age-associated expression of FcRn
revealed organ-specific patterns of ontogeny. Two-fold increases in FcRn expression
were observed in liver and lungs of 10 days old mice, whereas the FcRn expression in
kidneys was doubled in 10- and 42-days old mice. This ontogeny of FcRn expression
could not be correlated with the prolonged half-life of AMG589 that was observed in 42
day old mice. Although a doubling of FcRn expression was observed in mouse kidneys at
this age, the contribution of this organ to the overall elimination processes of mAbs
seems to be limited. Moreover, the function of FcRn expressed in kidneys is still
controversial. The negligible influence of the ontogeny of FcRn expression on the
pharmacokinetics of AMG589 in various age groups of mice was confirmed by the
population pharmacokinetic analysis. The population pharmacokinetic analysis revealed
that after the effect of body weight was adjusted by allometric scaling, age and FcRn
expression in skin were the additional factors that influenced the pharmacokinetics of
AMG589 in different age groups of mice. The volume of distribution of AMG589 was
affected by age with decreasing volume of distribution during development. Interestingly,
variability in the clearance of AMG589 could be partially explained by the expression of
FcRn in the skin, even though FcRn expression in skin did not show any ontogeny.
Although the experimental results in mice suggested three significant factors (body
weight, age, and FcRn expression in the skin) that should be considered during dosage
regimen design for mAbs, there are several limitations that might limit the generalization
of this finding to humans. One of these limitations is potential species differences in
developmental growth rate and the ontogenic pattern of FcRn expression. Regardless of
the species difference in physiology, however, body weight should be taken into account
during the dosage regimen design, especially for pediatric patients who usually exhibit an
expeditious increase in body size at an early age.
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The findings in this dissertation have highlighted some challenges and
determinants that should be considered during the pharmacokinetic interpretation and the
dosage regimen design for therapeutic proteins. To explore the error in the conventional
bioavailability estimation of therapeutic proteins that undergo TMDD, potential effects of
FcRn were considered to have a negligible effect on the pharmacokinetics of the model
drugs used. Similarly, TMDD was not considered to be a relevant pharmacokinetic
process in the disposition of AMG589 in mice. In reality, however, these two factors may
affect some therapeutic proteins, depending on the contribution of each process to the
overall pharmacokinetics. Moreover, other processes and determinants of drug
disposition of therapeutic proteins, VXFKDVLPPXQRJHQLFLW\DQGFOHDUDQFHWKURXJK)FȖreceptors and other proteolytic processes, may affect and further complicate the
pharmacokinetic behavior of proteins. Although a thorough understanding of the role and
limitations of each of these processes is necessary to fully understand the disposition of
individual therapeutic proteins, the findings in the studies presented in this dissertation
should be able to be generalized to other therapeutic proteins with similar
pharmacokinetic properties.
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Table A-1.

Dose effect on the bioavailability estimation of filgrastim with reference bioavailability (Fref) equals to 1.0a

IV dose
(g/kg)
0.01
0.05
0.1
0.5
1
2.5
5
10
50
100
500
1000
1500
5000
10000

SC dose (g/kg)
0.01

0.05

0.1

0.5

1

2.5

5

10

50

100

500

1000

1500

5000

10000

0.991
(-0.936)
0.961
(-3.87)
0.909
(-9.13)
0.500
(-50.0)
0.378
(-62.2)
0.306
(-69.4)
0.281
(-71.9)
0.267
(-73.3)
0.254
(-74.6)
0.252
(-74.8)
0.250
(-75.0)
0.250
(-75.0)
0.250
(-75.0)
0.250
(-75.0)
0.250
(-75.0)

1.01
(1.49)
0.985
(-1.52)
0.931
(-6.91)
0.512
(-48.8)
0.387
(-61.3)
0.313
(-68.7)
0.288
(-71.2)
0.273
(-72.7)
0.260
(-74.0)
0.258
(-74.2)
0.257
(-74.3)
0.256
(-74.4)
0.256
(-74.4)
0.256
(-74.4)
0.256
(-74.4)

1.05
(5.21)
1.02
(2.09)
0.965
(-3.49)
0.531
(-46.9)
0.402
(-59.8)
0.325
(-67.5)
0.298
(-70.2)
0.284
(-71.6)
0.270
(-73.0)
0.268
(-73.2)
0.266
(-73.4)
0.266
(-73.4)
0.266
(-73.4)
0.265
(-73.5)
0.265
(-73.5)

1.59
(59.4)
1.55
(54.7)
1.46
(46.2)
0.804
(-19.6)
0.608
(-39.2)
0.492
(-50.8)
0.452
(-54.8)
0.430
(-57.0)
0.409
(-59.1)
0.406
(-59.4)
0.403
(-59.7)
0.402
(-59.8)
0.402
(-59.8)
0.402
(-59.8)
0.402
(-59.8)

2.29
(129)
2.22
(122)
2.10
(110.)
1.16
(15.6)
0.875
(-12.5)
0.708
(-29.2)
0.650
(-35.0)
0.618
(-38.2)
0.588
(-41.2)
0.584
(-41.6)
0.580
(-42.0)
0.579
(-42.1)
0.579
(-42.1)
0.578
(-42.2)
0.578
(-42.2)

3.07
(207)
2.98
(198)
2.82
(182)
1.55
(55.0)
1.17
(17.3)
0.949
(-5.12)
0.871
(-12.9)
0.828
(-17.2)
0.788
(-21.2)
0.782
(-21.8)
0.777
(-22.3)
0.776
(-22.4)
0.775
(-22.5)
0.775
(-22.5)
0.775
(-22.5)

3.44
(244)
3.34
(234)
3.15
(215)
1.73
(73.4)
1.31
(31.3)
1.06
(6.20)
0.974
(-2.57)
0.927
(-7.33)
0.882
(-11.8)
0.876
(-12.4)
0.869
(-13.1)
0.868
(-13.2)
0.868
(-13.2)
0.867
(-13.3)
0.867
(-13.3)

3.66
(266)
3.55
(255)
3.36
(236)
1.85
(84.7)
1.40
(39.8)
1.13
(13.1)
1.04
(3.77)
0.987
(-1.30)
0.940
(-6.03)
0.932
(-6.75)
0.926
(-7.42)
0.925
(-7.52)
0.924
(-7.56)
0.924
(-7.61)
0.924
(-7.62)

3.89
(289)
3.77
(277)
3.56
(256)
1.96
(96.0)
1.48
(48.3)
1.20
(20.0)
1.10
(10.1)
1.05
(4.72)
0.997
(-0.292)
0.989
(-1.06)
0.982
(-1.78)
0.981
(-1.88)
0.981
(-1.92)
0.980
(-1.97)
0.980
(-1.99)

3.92
(292)
3.80
(280.)
3.60
(260.)
1.98
(97.8)
1.50
(49.7)
1.21
(21.1)
1.11
(11.1)
1.06
(5.67)
1.01
(0.613)
0.998
(-0.164)
0.991
(-0.884)
0.990
(-0.990)
0.990
(-1.03)
0.989
(-1.09)
0.989
(-1.10)

3.95
(295)
3.84
(284)
3.63
(263)
1.99
(99.4)
1.51
(50.9)
1.22
(22.1)
1.12
(12.0)
1.07
(6.55)
1.01
(1.45)
1.01
(0.668)
0.999
(-0.0584)
0.998
(-0.165)
0.998
(-0.203)
0.997
(-0.261)
0.997
(-0.275)

3.96
(296)
3.84
(284)
3.63
(263)
2.00
(99.7)
1.51
(51.1)
1.22
(22.3)
1.12
(12.2)
1.07
(6.68)
1.02
(1.57)
1.01
(0.790)
1.00
(0.0632)
1.00
(-0.0437)
0.999
(-0.0819)
0.999
(-0.140)
0.998
(-0.154)

3.96
(296)
3.84
(284)
3.63
(263)
2.00
(99.8)
1.51
(51.2)
1.22
(22.3)
1.12
(12.2)
1.07
(6.73)
1.02
(1.62)
1.01
(0.834)
1.00
(0.106)
1.00
(0.000581)
1.00
(-0.0388)
0.999
(-0.0969)
0.999
(-0.111)

3.96
(296)
3.85
(285)
3.64
(264)
2.00
(99.9)
1.51
(51.3)
1.22
(22.4)
1.12
(12.3)
1.07
(6.79)
1.02
(1.69)
1.01
(0.900)
1.00
(0.172)
1.00
(0.0648)
1.00
(0.0266)
1.00
(-0.0316)
1.00
(-0.0455)

3.96
(296)
3.85
(285)
3.64
(264)
2.00
(99.9)
1.51
(51.3)
1.22
(22.4)
1.12
(12.3)
1.07
(6.81)
1.02
(1.70)
1.01
(0.916)
1.00
(0.187)
1.00
(0.0803)
1.00
(0.0421)
1.00
(-0.0161)
1.00
(-0.0299)

a

%Prediction errors are reported in the brackets. Bioavailabilities with minimum bias are reported in bold.
Light gray area demonstrates overestimated bioavailability with prediction error exceeds 20%.
Dark gray area demonstrates underestimated bioavailability with prediction error exceeds 20%.
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Dose effect on the bioavailability estimation of denosumab with the reference bioavailability (Fref) equals to 1.0a

Table A-2.

IV dose
(mg)
0.66
1.98
6
6.6
14
15
19.8
30
60
66
100
120
198
210

0.66
0.919
(-8.13)
0.440
(-56.0)
0.129
(-87.1)
0.119
(-88.1)
0.0754
(-92.5)
0.0732
(-92.7)
0.0658
(-93.4)
0.0583
(-94.2)
0.0510
(-94.9)
0.0503
(-95.0)
0.0479
(-95.2)
0.0471
(-95.3)
0.0454
(-95.5)
0.0453
(-95.5)

1.98
1.70
(70.1)
0.815
(-18.5)
0.239
(-76.1)
0.220
(-78.0)
0.140
(-86.0)
0.136
(-86.4)
0.122
(-87.8)
0.108
(-89.2)
0.0944
(-90.6)
0.0931
(-90.7)
0.0887
(-91.1)
0.0872
(-91.3)
0.0841
(-91.6)
0.0838
(-91.6)

6
6.57
(557)
3.15
(215)
0.921
(-7.87)
0.851
(-14.9)
0.539
(-46.1)
0.523
(-47.7)
0.471
(-52.9)
0.417
(-58.3)
0.365
(-63.5)
0.360
(-64.0)
0.343
(-65.7)
0.337
(-66.3)
0.325
(-67.5)
0.324
(-67.6)

6.6
7.18
(618)
3.44
(244)
1.01
(0.649)
0.930
(-6.99)
0.589
(-41.1)
0.572
(-42.8)
0.514
(-48.6)
0.455
(-54.5)
0.398
(-60.2)
0.393
(-60.7)
0.374
(-62.6)
0.368
(-63.2)
0.355
(-64.5)
0.354
(-64.6)

14
11.8
(1084)
5.67
(467)
1.66
(66.0)
1.53
(53.4)
0.972
(-2.79)
0.943
(-5.67)
0.848
(-15.2)
0.751
(-24.9)
0.657
(-34.3)
0.648
(-35.2)
0.618
(-38.2)
0.607
(-39.3)
0.585
(-41.5)
0.583
(-41.7)

15
12.2
(1123)
5.86
(486)
1.71
(71.5)
1.58
(58.4)
1.00
(0.398)
0.974
(-2.58)
0.876
(-12.4)
0.776
(-22.4)
0.678
(-32.2)
0.669
(-33.1)
0.638
(-36.2)
0.627
(-37.3)
0.604
(-39.6)
0.602
(-39.8)

SC dose (mg)
19.8
30
13.7
15.6
(1269) (1457)
6.56
7.46
(556)
(646)
1.92
2.18
(92.0)
(118)
1.77
2.02
(77.4)
(102)
1.12
1.28
(12.4)
(27.9)
1.09
1.241
(9.10)
(24.1)
1.12
0.981
(-1.88) (11.6)
0.869
0.988
(-13.1) (-1.20)
0.760
0.864
(-24.0) (-13.6)
0.750
0.853
(-25.0) (-14.7)
0.714
0.812
(-28.6) (-18.8)
0.702
0.799
(-29.8) (-20.1)
0.677
0.770
(-32.3) (-23.0)
0.674
0.767
(-32.6) (-23.3)

a

60
17.9
(1691)
8.58
(758)
2.51
(151)
2.32
(132)
1.47
(47.1)
1.43
(42.7)
1.283
(28.3)
1.14
(13.6)
0.994
(-0.621)
0.981
(-1.95)
0.934
(-6.57)
0.919
(-8.14)
0.885
(-11.5)
0.882
(-11.8)

66
18.2
(1716)
8.70
(770.)
2.55
(155)
2.35
(135)
1.49
(49.1)
1.45
(44.7)
1.30
(30.1)
1.15
(15.2)
1.01
(0.773)
0.994
(-0.572)
0.947
(-5.26)
0.932
(-6.85)
0.898
(-10.2)
0.894
(-10.6)

100
19.1
(1809)
9.14
(814)
2.68
(168)
2.47
(147)
1.57
(56.8)
1.52
(52.1)
1.37
(36.8)
1.21
(21.1)
1.06
(5.94)
1.05
(4.53)
0.996
(-0.407)
0.979
(-2.07)
0.944
(-5.63)
0.940
(-5.97)

120
19.4
(1843)
9.31
(831)
2.72
(172)
2.52
(152)
1.60
(59.5)
1.55
(54.8)
1.39
(39.2)
1.23
(23.3)
1.08
(7.81)
1.06
(6.37)
1.01
(1.35)
0.997
(-0.342)
0.960
(-3.96)
0.957
(-4.30)

%Prediction errors are reported in the brackets. Bioavailabilities with minimum bias are reported in bold.
Light gray area demonstrates overestimated bioavailability with prediction error exceeds 20%.
Dark gray area demonstrates underestimated bioavailability with prediction error exceeds 20%.
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198
20.2
(1919)
9.67
(867)
2.83
(183)
2.62
(162)
1.66
(65.8)
1.61
(60.9)
1.45
(44.7)
1.28
(28.1)
1.12
(12.0)
1.11
(10.5)
1.05
(5.32)
1.04
(3.56)
0.998
(-0.202)
0.994
(-0.560)

210
20.3
(1926)
9.70
(870.)
2.84
(184)
2.63
(163)
1.66
(66.4)
1.61
(61.5)
1.45
(45.2)
1.29
(28.6)
1.12
(12.4)
1.11
(10.9)
1.06
(5.70)
1.04
(3.94)
1.00
(0.162)
0.998
(-0.197)

Normalized FcRn Expression
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Figure B-1. Ontogeny of FcRn protein expression in mouse skin
No significant difference in the relative FcRn protein expression was observed in the skin
of 2-, 10-, 21-, 42-, and 70-day old mice. The difference of relative FcRn protein
expression between 20 ђg and 40 ђg loading sample sets was statistically significant (p <
0.0001).
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Figure B-2. Ontogeny of FcRn protein expression in mouse liver
Relative expression of FcRn protein in mouse liver was significantly increased in 10-day
old mice compared to other age groups. The statistical p-values are reported above the
line associated with each pair of comparison. The difference of relative FcRn protein
expression between 20 g and 40 g loading sample sets was statistically significant (p <
0.0001).
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Figure B-3. Ontogeny of FcRn protein expression in mouse kidney
Relative expression of FcRn protein in mouse kidney was significantly increased in 10and 42-day old mice compared to other age groups. The significant statistical p-values are
reported above the line associated with each pair of comparison. The relative FcRn
protein expressions in 20 g and 40 g loading sample sets were statistically significantly
different (p = 0.0240).
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Figure B-4. Ontogeny of FcRn protein expression in mouse lung
Relative expression of FcRn protein in mouse lung was significantly increased in 10-day
old mice compared to 2- and 70-day old animals. The significant statistical p-values are
reported above the line associated with each pair of comparison. The relative FcRn
protein expressions in 20 g and 40 g loading sample sets were statistically significantly
different (p = 0.0005).
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Figure B-5. Ontogeny of FcRn protein expression in mouse spleen
There was no significant difference in the relative expression of FcRn protein in mouse
spleen among all age groups. The difference of relative FcRn protein expressions
between 20 g and 40 g loading sample sets was statistically significant (p = 0.008).
There was no result of 40 ђg loading set in spleen from 2-day old mice.
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Figure B-6. Protein expression of FcRn and GAPDH in various organs of a 70
days old mouse
Protein that was loaded in each lane were protein ladder (A), recombinant mouse FcRn
(positive control; B), Bovine serum albumin (negative control; C), total protein extracts
from liver (D), kidney (E), lung (F), heart (G), spleen (H), skin (I), stomach (J), and
pancreas (K) of a 70 days old C57BL/6J mouse.
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Table B-1.
Expression ratio of FcRn monomer and dimer per total FcRn protein
expression and total FcRn expression in mouse liver across different age groups
Age
Day 2
Day 10
Day 21
Day 42
Day 70
a

Monomer
Mean
%RSD
0.84
15.58
0.93
7.37
0.71
22.91
0.70
24.80
0.68
23.88

Complex
Mean
%RSD
0.16
83.57
a
0.07
103.11
0.29
56.30
0.30
58.07
0.32
51.13

Monomer + Complex
Mean
%RSD
0.73
36.96
1.57
31.08
1.13
42.64
1.19
28.99
1.02
34.19

p < 0.005 when compared to mice from day 21, and 70 age groups
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Figure B-7. Expression of FcRn monomer and total FcRn protein in mouse liver
across all age groups
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APPENDIX C. CHAPTER 5 SUPPLEMENTAL RESULTS

Figure C-1. Correlation between inter-subject variability on CL (ETA1) and
covariates (sex, age, FcRn expression in skin, and FcRn expression in liver)

Figure C-2. Correlation between inter-subject variability on CL (ETA1) and
covariates (FcRn expressions in kidney, lung, and spleen)
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Figure C-3. Correlation between inter-subject variability on V (ETA2) and
covariates (sex, age, FcRn expression in skin, and FcRn expression in liver)

Figure C-4. Correlation between inter-subject variability on V (ETA2) and
covariates (FcRn expressions in kidney, lung, and spleen)
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Figure C-5. Correlation between inter-subject variability on Ka (ETA3) and
covariates (sex, age, FcRn expression in skin, and FcRn expression in liver)

Figure C-6. Correlation between inter-subject variability on Ka (ETA3) and
covariates (FcRn expressions in kidney, lung, and spleen)
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Figure C-7.

Goodness-of-fit plots of the final model applied in full dataset

105

VITA
Wararat Limothai, daughter of Mr. Sirichai Limothai and Mrs. Narumon SaeUng, was born in 1981 in Bangkok, Thailand. She graduated from Faculty of
Pharmaceutical Sciences, Chulalongkorn University with B.Sc. degree in 2004. After
graduation, she worked as a researcher in Research and Development Institute, The
Government Pharmaceutical Organization (GPO) in Thailand. After working for 4 years,
she received a scholarship from GPO for pursuing a Ph.D. degree. In 2008, she enrolled
in the Ph.D. program at the University of Tennessee Health Science Center under the
direction of Dr. Bernd Meibohm in the Department of Pharmaceutical Sciences. In 2014,
she moved back to Thailand and started working as a senior researcher in R&D Institute,
GPO. She anticipates completing her Ph.D. by December 2015.

106

